# Patent

## Title
Antibacterial cephalosporins

## Abstract

A compound of formula




wherein Ac, R1 and R2 have various meanings, a process for a preparation thereof and its use as a pharmaceutical, i.e. as antibacterial agent.

## Background
The present invention relates to antibacterial compounds which are 7-acylamino-3-(imino)methyl cephalosporins.
Particularly the present invention provides a compound of formula




wherein

    R1 denotes hydrogen or an ester moiety,
    R2 denotes a group of formula






    
    
        wherein
        Y denotes hydrogen, alkyl, alkenyl, acyl, carbamoyl or aryl
        R4 denotes hydrogen, alkyl, alkenyl, cycloalkyl, aryl, acyl or heterocyclyl
        R5 denotes hydrogen, alkyl, alkenyl, cycloalkyl, aryl, heterocyclyl, or a group of formula
    
    






    
    
         wherein
        
            R7 denotes alkyl or aryl
            R8 denotes hydrogen, cycloalkyl or alkyl
            R9 denotes hydrogen or alkyl
            R10 denotes hydrogen, alkyl, hydroxy, amino, phenyl, alkenyl, cycloalkyl,aryl, heterocyclyl or a group of formula

—N═CH-Phe
            
                wherein Phe denotes aryl
            
            
            R9 and R10 together with the nitrogen atom denote heterocyclyl,
            Z denotes oxygen, sulphur or N—R13, wherein
            
                R13 denotes hydrogen, alkyl or cycloalkyl
            
            
            R11 denotes hydrogen, alkyl, aryl, cycloalkyl or heterocyclyl, or
            R4 and R5 together with the nitrogen atom denote heterocyclyl,
            R6 denotes heterocyclyl, and
        
        
    
    
    Ac denotes
    (i) a group






    (ii) a group of formula






wherein

    
    
        B denotes N or CH
        Z1 denotes aryl, cycloalkyl, 1,4-cyclohexadienyl or heterocyclyl
        Z2 denotes hydrogen, alkyl or —CH2COOZ5, wherein
        
            Z5 denotes hydrogen, alkyl or cycloalkyl
        
        
        Z3 denotes hydrogen or alkyl
        Z4 denotes hydrogen or an organic radical
        D denotes oxygen or CH2.
    
    


A subgroup of the invention comprises any of the individual groups of significances mentioned therein.
R1 may be hydrogen or an ester moiety. An ester moiety includes alkyl, preferably C1-6alkyl; arylalkyl, for example benzyl, alkoxybenzyl, such as 4-methoxybenzyl; indanyl, phthalidyl, alkoxymethyl, e.g. methoxymethyl; (C1-6)alkanoyloxy(C1-6)alkyl, (C1-6)alkoxy-carbonyl-oxy(C1-6)alkyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl and ester moieties which form with the COO— group a physiologically hydrolysable and acceptable ester, e.g. such known to be hydrolysable ester groups in the field of cephalosporins. A compound of formula I may thus be in the form of an physiologically-hydrolysable and -acceptable ester. By physiologically-hydrolysable and -acceptable esters as used herein is meant an ester in which the COO— group is esterified and which is hydrolysable under physiological conditions to yield an acid which is itself physilogically tolerable at dosages to be administered. The term is thus to be understood as defining regular pro-drug forms. An ester moiety may be preferably a group which is easily hydrolysable under physiological conditions. Such esters may be administered preferably orally. Parenteral administration may be indicated if the ester per se is an active compound or, if hydrolysis occurs in the blood.
Y may be preferably hydrogen, unsubstituted alkyl or alkyl substituted by e.g. hydroxy or, preferably the residue of a carboxylic acid. The residue of a carboxylic acid includes the residue of a carboxylic acid in free form or in salt form, of a carboxylic acid ester and of a carboxylic acid amide. The carboxylic acid is, for example, a C1-7 carboxylic acid, preferably a C1-5 aliphatic carboxylic acid, an alkyl part thereof including lower alkyl. The alkoxy group of a carboxylic acid ester includes C1-6, preferably C1-4alkoxy. Alkyl is preferably lower alkyl. The alkyl group is preferably unsubstituted or substituted by carboxylic acid residues.
R4 may be preferably hydrogen or alkyl, for example lower alkyl.
R5 may be preferably hydrogen; unsubstituted alkyl; alkyl substituted for example by oxo, alkyl or halogenated alkyl; amino; one or several fold substituted heterocyclyl; or a group of formulae IId, IIe, IIf. Heterocyclyl includes unsaturated or saturated heterocyclyl having, e.g. 5 or 6 ring members and, for example, 1 to 3 hetero atoms, such as N, O, S, preferably N, or condensed heterocyclyl, such as benzothiazolyl.
R4 and R5 together with the nitrogen atom may be heterocyclyl, having preferably 5 or 6 ring members and having preferably 1 to 3 heteroatoms, for example N atoms; which may be unsubstituted heterocyclyl; or one or several fold substituted heterocyclyl, for example by oxo, amino, alkyl.
R6 may be saturated or unsaturated heterocyclyl; having preferably 5 or 6 ring members and having for example 1 or 2 nitrogen hetero atoms; for example unsubstituted heterocylclyl; or one or several fold substituted heterocyclyl, for example by amino, alkyl or thiono.
R7 may be preferably alkyl.
R8 may be preferably alkyl or cycloalkyl.
R9 may be preferably hydrogen or lower alkyl.
R13 may be preferably alkyl.
R10 may be preferably hydrogen; aryl; alkenyl; cycloalkyl; unsubstituted alkyl; substituted alkyl, for example by hydroxy, halogen, heterocyclyl, such as pyridyl, amino, for example N(alkyl)2 or N+(alkyl)3; or a group

—N═CH—Ar

wherein Ar denotes heterocyclyl; unsubstituted aryl; or substituted aryl, for example by hydroxy or alkoxy; preferably aryl which may be preferably phenyl.

R9 and R10 together with the nitrogen atom may be heterocyclyl having preferably 5 or 6 ring members and 1 to 3 hetero atoms such as N, S, O, for example N, O; preferably saturated heterocyclyl. Heterocyclyl includes unsubstituted heterocyclyl, or substituted heterocyclyl, for example by acyl, formyl, alkyl, for example lower alkyl. Examples include pyrrolidine, morpholine, piperazine, preferably piperazine.
R11 may be preferably hydrogen; unsubstituted alkyl; substituted alkyl, for example by aminoalkyl, diaminoalkyl, triaminoalkyl; aryl, such as dihydroxyphenyl; cycloalkyl; or unsubstituted heterocyclyl; or substituted heterocyclyl, for example by alkyl, thiono heterocyclyl; heterocyclyl having preferably 5 or 6 ring members and 1 to 3 hetero, preferably N atoms.
If not otherwise stated therein any carbon containing group may contain up to 20 carbon atoms, e.g. alkyl includes C1-20, e.g. C1-8 alkyl. Lower alkyl includes e.g. C1-4alkyl, preferably C1-2alkyl. Alkenyl includes C2-20, e.g. C2-8 alkenyl. Lower alkenyl includes e.g. C3-5alkenyl, preferably C3alkyl. Cycloalkyl includes, for example, C3-6cycloalkyl, particularly C3, C5 or C6cycloalkyl. Alkyl, alkenyl and cycloalkyl include unsubstituted alkyl, alkenyl and cycloalkyl; and, substituted alkyl, alkenyl and cycloalkyl, for example, by halogen, a sulphonic acid derivative, such as SO3H, CF3, hydroxy, alkoxy, acyl, alkylamino, pyridyl. Cycloalkyl is preferably unsubstituted. Acyl includes C1-12, e.g. C1-6acyl, particularly C1-4acyl. Acyl includes unsubstituted acyl and substituted acyl, for example, by hydroxy, alkoxy, amino. Aryl includes phenyl. Aryl may be unsubstituted aryl or substituted aryl, for example by alkyl, alkoxy, acyl, halogen, hydroxy, unprotected or protected amino. Alkoxy includes alkoxy wherein the alkyl part is as defined above. Heterocyclyl includes heterocyclyl having 5 or 6 ring members and 1 to 3 nitrogen, sulphur and/or oxygen hetero atoms including, for example, condensed heterocyclyl, such as for example benzthiazolyl. Heterocyclyl includes further unsubstituted hetercyclyl and substituted heterocyclyl, for example by oxo, alkoxy, hydroxy, thiono, mercapto, alkylthio, imino, alkylamino, alkylimino, amino, halogen, acyl, CF3, CHO, alkyl, cycloalkyl. Carbamoyl includes the carbamoyl group or carbamoyl having alkyl and aryl residues. Z1 denotes unsubstituted cycloalkyl, 1,4-cyclohexadienyl, heterocyclyl or aryl; and one or several fold substituted cycloalkyl, 1,4-cyclohexadiene, heterocyclyl or aryl; for example by carboxyl, amino, nitro, cyano, lower alkyl, lower alkoxy, hydroxy, halogen, —CO—N(Z5Z6), —N(Z6)—COOZ7, Z6CO—, Z6OCO—, Z6COO—.
Z2 denotes hydrogen; CH2COOZ5; unsubstituted lower alkyl; one or several fold substituted lower alkyl, for example by carboxyl, amino, nitro, cyano, lower alkyl, lower alkoxy, hydroxy, halogen, —COZ5Z6, —N(Z6)—COOZ7, Z6CO—, Z6OCO— or Z6COO—.
Z3 denotes hydrogen or lower alkyl.
Z4 denotes hydrogen or an organic radical; preferably hydrogen; lower alkyl; cycloalkyl; aralkyl; acyl; carboxyalkyl; Z6CO—, —C(Z7Z8)COOZ6 or, preferably in the case that Z1 in group




    denotes a group 2-amino-thiazol-4yl or 2-amino-thia-3,5-diazol4yl,
    Z4 denotes a group of formula






    
    
        wherein
        Z9 and Z10 independently of one another denote hydrogen or protected or unprotected carboxyl
        Z11 denotes hydrogen or acetyl,
        Z12 denotes unprotected or protected carboxyl,
        Z13 denotes hydrogen or methyl,
        Z14 denotes hydrogen; chloro; unprotected or protected carboxyl; methyl; isopropyl; hydroxy; methoxy; acetoxy,
        Z15 and Z16 denote independently from one another hydrogen, hydroxy, methoxy, ethoxy, 2-methoxyethoxymethoxy, acetoxy, chloroacetoxy, butanoyloxy, methansulfonyloxy, p-toluenesulfonyloxy, amino, acetylamino, benzyloxycarbonylamino or methansulfonyl; or,
        Z15 and Z16 denote together ethylendioxy or carbonyldioxy,
        Z17 denotes hydrogen, hydroxy, acetoxy, methyl, methoxy, chloroacetoxy, with the proviso, that not all of Z14, Z15, Z16 and Z17 denote hydrogen,
        Z18 and Z19 denote independently of one another hydrogen or methyl,
        Z20, Z21, Z22, Z23 and Z24 denote independently of one another hydrogen, halogen or hydroxy,
        Z25 and Z26 denote independently from one another hydrogen; C1-5alkyl; unsubstituted phenyl; or substituted phenyl,
        Z27 denotes unsubstituted lower alkyl; or substituted lower alkyl,
        Z28 and Z29 denote independently of one another hydrogen or hydroxy, and n denotes 0 or 1,
    
    
    Z5 denotes hydrogen, alkyl, preferably lower alkyl,
    Z6 and Z7 independently of one another denote hydrogen or alkyl, preferably lower alkyl,
    Z6 and Z7 together with the carbon atom denote cycloalkyl, and
    Z5 and Z6 together denote cycloalkyl.
    Z4 may be selected from the following groups:






For example, Ac may denote a group of formula




Preferably Ac denotes a compound of formula




wherein

    W denotes CH or N
    V denotes CH or N—O and
    R3 denotes hydrogen, acyl, carboxyl, alkyl.


The configuration of R3 in group of —C═V—R3 may be syn [(Z)] and anti [(E)] and is preferably syn [(Z)].
If R3 denotes alkyl, R3 includes unsubstituted alkyl or substituted alkyl, for example by halogen, carboxyl. Preferably W denotes CH.
In another aspect the present invention provides a compound of formula




wherein

    W denotes CH or N
    V denotes CH or N—O
    R1 denotes hydrogen or an ester moiety,
    R2 denotes a group of formula






wherein

    
    
        Y denotes hydrogen; unsubstituted lower alkyl; or substituted lower alkyl, by the residue of a carboxylic acid, a carboxylic acid ester or a carboxylic acid amide,
        R4 denotes hydrogen, phenyl, cycloalkyl or lower alkyl
        R5 denotes hydrogen, lower alkyl, heterocyclyl or a group of formulae
    
    






    
    
         wherein
        
            R7 denotes lower alkyl
            R8 denotes hydrogen, cycloalkyl or lower alkyl
            R9 denotes hydrogen or lower alkyl,
            R10 denotes hydrogen, hydroxy; amino; phenyl; alkenyl; cycloalkyl; heterocyclyl; unsubstituted alkyl; substituted alkyl, by CF3, OH, alkoxy, carboxyl, halogen, amino, monoalkylamino, dialkylamino, trialkylamino, pyridyl or a a sulfonic acid residue; a group of formula
        
        
    
    






    
    
        
        
            
            
                wherein
                R12 denotes hydrogen or lower alkyl,
            
            
            Z denotes oxygen, sulphur, or N—R13, wherein
            
                R13 denotes hydrogen or lower alkyl, and
            
            
            R11 denotes hydrogen; dihydroxyphenyl; cycloalkyl; heterocyclyl; unsubstituted lower alkyl; substituted lower alkyl by pyridyl or monoalkylamino, dialkylamino or trialkylamino; and,
            R4 and R5 and/or R9 and R10 independently of one another together with the nitrogen denote heterocyclyl,
            R6 denotes heterocyclyl, and
        
        
    
    
    R3 denotes hydrogen; acyl; carboxyl; unsubstituted alkyl; substituted alkyl by halogen or carboxyl.


In another aspect the present invention provides a compound of formula




wherein

    R1p is the same as R1 in formula I,
    Ac is as defined in formula I,
    R2p denotes a group of formulae






wherein

    
    
        Yp is the same as Y in formula IA,
        R4p is the same as R4 in formula IA, and
        R5p denotes hydrogen, cycloalkyl, lower alkyl or a group of formula
    
    






    
    
        wherein
        
            R8p is the same as R8 in formula IA,
            Zp is the same as Z in formula IA,
            R9p is the same as R9 in formula IA,
            R7p denotes methyl,
            R10p denotes hydrogen, lower alkyl or hydroxy, and
            R4p and R5p and/or R9p and R10p independently of one another together with the nitrogen denote heterocyclyl, and
        
        
        a compound of formulae IIbp, IIdp and IIep denote any tautomeric form, in free form, or, where such a form exists, in form of an acid addition salt, inner salt, quaternary salt or hydrate thereof.
    
    


In another aspect the present invention provides a compound of formula




wherein

    Ac is as defined in formula I
    R1q is he same as R1 in formula IA, and
    R2q denotes a group of formula






wherein

    Yq is the same as Y in formula IA,
    R4q is the same as R4 in formula IA, and
    R5q denotes hydrogen, cycloalkyl, lower alkyl or a group of formulae






wherein

    R7q is the same as R7 in formula IA,
    R8q is the same as R8 in formula IA,
    Zq is the same as Z in formula IA,
    R9q is the same as R9 in formula IA,
    R10q denotes hydrogen, lower alkyl or hydroxy, and
    R4q and R5q and/or R9q and R10q independently of one another together with the nitrogen denote heterocyclyl, and
    a compound of formulae IIbp, IIdp and IIep denote any tautomeric form, in free form, or, where such a form exists, in form of an acid addition salt, inner salt, quaternary salt or hydrate thereof.


In a further aspect the present invention provides a compound of formula




wherein

    
    
        R1s is the same as R1 in formula IA,
        Vs is the same as V in formula IA,
        Ws is the same as W in formula IA
        R3s denotes hydrogen, lower acyl; unsubstituted alkyl; substituted lower alkyl, by carboxyl and/or fluoro; and
        R2s denotes a group of formula
    
    






    
    
        wherein
        Ys denotes hydrogen; unsubstituted lower alkyl; or substituted alkyl by carboxyl,
        R4s denotes hydrogen or lower alkyl, and
        R5s denotes hydrogen; saturated or unsaturated, unsubstituted heterocyclyl having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms; saturated or unsaturated one or several fold substituted heterocyclyl by oxo, lower alkyl, amino or CF3, having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms; benzothiazolyl; or a group of formula
    
    






    
    
        wherein
        
            Zs is the same as Z in formula I,
            R7s denotes lower alkyl,
            R8s denotes hydrogen, cycloalkyl or lower alkyl,
            R9s denotes hydrogen or lower alkyl,
            R10s denotes hydrogen; phenyl; allyl; cycloalkyl; unsubstituted alkyl; substituted alkyl by CF3, dialkylamino, trialkylamino, hydroxy, pyridyl or SO3H, and
            R11s denotes hydrogen; pyridyl; cycloalkyl; unsubstituted lower alkyl; substituted lower alkyl by pyridyl or trialkylamino; saturated or unsaturated heterocyclyl having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms; or one or several fold substituted heterocyclyl by lower alkyl and/or thiono, having 5 or 6 ring members and 1 to 3 nitrogen hetero atoms;
            R4s and R5s together with the nitrogen atom denote heterocyclyl selected from saturated, unsubstituted heterocyclyl having 5 or 6 ring members and 1 or 2 nitrogen hetero atoms; saturated, one or several fold substituted heterocyclyl by oxo or lower alkyl, having 5 or 6 ring members and 1 or 2 nitrogen hetero atoms; and/or
            R9s and R10s together with the nitrogen atom denote saturated, unsubstituted heterocyclyl having 5 or 6 ring members and 1 or 2 nitrogen and/or oxygen hetero atoms; unsaturated, one or several fold substituted heterocyclyl by CHO or lower alkyl, having 5 or 6 ring members and 1 or 2 nitrogen and/or oxygen hetero atoms.
        
        
    
    


In another aspect the present invention provides a compound of formula




wherein

    W denotes CH or N
    V denotes CH or N—O
    R1 denotes hydrogen or an ester moiety, and
    R2 denotes a group of formula

—N(R4R5)  IIb

wherein

    R4 is as defined in claim 1 and
    R5 denotes a group of formula






    
    
        wherein
        Z denotes —N—R13, wherein
        
            R13 is as defined in claim 1, and
            R9 and R10 together with the nitrogen atom denote heterocyclyl which is a piperazinyl.
        
        
    
    


In another aspect the present invention provides a compound selected from 7-[[(2-amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]amino]-3-[[(aminoiminomethyl)-hydrazono]methyl]-3-cephem-4-carboxylic acid (compound of Example 2), 7-[[(2-amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]-amino]-3-[[(piperazinoiminomethyl)-hydrazono]methyl]-3-cephem-4-carboxylic acid (compound of Example 96) 7-[[(5-Amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluormethoxyimino)acetyl]amino]-3-[[(piperazinoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (compound of Example 139).
A compound of formulae I, IA, Ip, Iq, Is, IVi, IVa and VIa may exist in equilibrium with tautomeric forms. The present invention includes a compound of formulae I, IA, Ip, Iq, Is IVi, IVa and VIa in any tautomeric form in which it may exists.
In another aspect the present invention provides a process for the production of a compound of formula I by reaction of a compound of formula




wherein Ac is as defined in formula I and

    a) either
    
        α) Rb denotes hydroxy and Rc and Rd together form a bond, or
        β) Rd denotes hydrogen, a cation, an ester forming group or a silyl group, and Rb and Rc together denote oxo,
        
            in free form or in form of an acid addition salt
        
        
        with a group of formula

H2N—R2  IV
        
            wherein R2 is as defined in formula I, or
        
        
    
    
    b) reacting a compound of formula






    
    
        wherein R1 and R2 are as defined in formula I, with a compound of formula

Ac—X′  VII

        wherein Ac is as defined in formula I and X′ denotes a leaving group.
    
    


If desired reactive groups may be protected with protecting groups, which may be, or, which are split off under the reaction conditions, or after termination of the reaction described above. A compound of formula I wherein R1 denotes hydrogen may be converted into a compound of formula I, wherein R1 denotes an carboxylic acid ester group. A compound of formula I may be isolated from the reaction mixture in conventional manner.
Process a) may be carried out as follows:
A compound of formula III in a solvent which is inert under the reaction conditions, such as water, a mixture of water and a lower alcohol and/or dioxane, or a dipolar aprotic solvent, for example dimethylformamide or dimethylsulfoxide, optionally mixed with an alcohol or water is reacted with a compound of formula IV at a temperature of about −20 to 50° C. An optimal pH may be adjusted by addition of an inorganic or organic acid or base. A compound of formula I thus obtained may be isolated in conventional manner, for example by addition of an anti-solvent or by chromatographic techniques.
Process b) may be carried out as follows:
The reaction may be carried out as conventional, e.g. a compound of formula VI may be reacted with a compound of formula VII in a solvent, for example dissolved or suspended in a mixture of acetone/water, for example at room temperature.
A reactive group may be protected, preferably by silyl protecting group technology. Suitable solvents include solvents which are inert under the reaction conditions, such as chlorinated hydrocarbons, nitriles, such as acetonitrile, ethers, such as tetrahydrofuran or a mixture of such solvents. Further suitable solvents include dipolar aprotic solvents, e.g. N,N-dimethylformamide. Protecting groups may be split off in conventional manner.
A starting compound of formula II may, for example, be obtained by

    a) reaction of a compound of formula






wherein either

    α) Ra denotes a salt of —NH2 with an inorganic or organic acid, R′b denotes hydroxy, and R′c and R′d denote together a bond, or
    β) Ra denotes NH2, R′d denotes hydrogen and R′b and R′c together denote oxo, with a silylation agent and,
    a compound obtained in step a) of formula






wherein Sil denotes a silyl group and either

    α) R′′b denotes —OSil and R′′c and R′′d together denote a bond
    β) R′′d denotes Sil and R′′b and R′′c together denote oxo

is acylated either directly in the reaction mixture or after isolation from the reaction mixture.



Acylation may be carried out in conventional manner.
A compound of formula IIIc may be obtained

    a) for the production of a compound of formula






    
    
        which is an the form of a salt of an inorganic or organic acid and wherein R′′′b denotes hydroxy and R′′′c and R′′′d together denote a bond,
        reacting a salt of an inorganic or organic acid of a compound of formula
    
    






    
    
        wherein
        
            R14 and R15 are the same or different and each denote hydrogen or an organic residue
        
        
        in an organic solvent optionally in the presence of water with ozone
    
    
    b) for the production of a compound of formula






    
    
        treating a compound of formula IIIe wherein R′′′b, R′′′c and R′′′d ar as defined above, with a base.
    
    


Compounds of formulae IV are partially new and may be obtained analogously to conventional methods, or, as described in the examples.
In another aspect the present invention provides a compound of formula

H2N—R2i  IVi

wherein

    
    
        R2i denotes a group of formula

—N(R4iR5i)  IIbi

wherein

        R4i is the same as R4 in formula I and denotes preferably hydrogen or alkyl and
        R5i denotes a group of formula
    
    






    
    
        wherein
        
            Zi denotes N—R13i, wherein
            
                R13i is the same as R13 in formula I and denotes preferably hydrogen or alkyl, and
            
            
            R9i and R10i together with the nitrogen atom denote heterocyclyl which is a piperazinyl; or
        
        
    
    
    R4i is the same as R4 in formula I and denotes preferably hydrogen, and
    R5i denotes a group of formula






    
    
        wherein
        
            R8i denotes alkyl, preferably at least C2 alkyl; or cycloalkyl, preferably cyclopropyl, and
            R7i denotes alkyl, preferably methyl; or
        
        
    
    
    R4i is the same as R4 in formula I and denotes preferably hydrogen or alkyl and
    R5i denotes a group of formula






    
    
        wherein
        Zi denotes N—R13i, wherein
        
            R13i denotes hydrogen, alkyl or cycloalkyl, preferably hydrogen or alkyl
        
        
        R9i denotes hydrogen and
        R10i denotes CH2CF3, C(CH3)3, OH or an alkyl group having at least 2 carbon atoms which is substituted by dialkyl amine or trialkyl ammonium, hydroxy; or
    
    
    R4i is the same as R4 in formula I and denotes preferably hydrogen
    R5i denotes a group of formula






    
    
        wherein
        Zi denotes N—R13i, wherein
        
            R13i denotes alkyl or cycloalkyl, preferably alkyl, and
        
        
        R9i and R10i together with the nitrogen atom denote heterocyclyl which is morpholyl or pyrrolidinyl; or
    
    
    R4i is the same as R4 in formula I and denotes preferably hydrogen
    R5i denotes a group of formula






    
    
        wherein
        Zi denotes N—R13i, wherein
        
            R13i denotes hydrogen, alkyl or cycloalkyl, preferably hydrogen, and
        
        
        R9i denotes hydrogen, and
        R10i denotes cycloalkyl, preferably cyclopropyl; or
    
    
    R4i is the same as R4 in formula I and denotes preferably hydrogen
    R5i denotes a group of formula






    
    
        wherein
        Zi denotes N—R13i, wherein
        
            R13i is the same as R13 in formula I and denotes preferably hydrogen,
        
        
        R9i denotes hydrogen or alkyl, preferably hydrogen, and
        R10i denotes a group

—N═CH-Phe

        wherein Phe denotes phenyl, preferably a dihydroxy phenyl, or
    
    
    R4i is the same as R4 in formula I and denotes preferably hydrogen
    R5i denotes a group of formula






    
    
        wherein
        Zi denotes N—R13i, wherein
        
            R13i denotes hydrogen, alkyl or cycloalkyl, preferably hydrogen,
            R11i denotes a dihydroxyphenyl or substituted pyrrolidyl by alkyl; or
        
        
        Zi denotes oxygen and
        
            R11i denotes the group of formula
        
        
    
    






In another aspect the present invention provides a compound of formula




wherein

    Rx is a group of formula






    Ry is NH and
    Rz is hydrogen; or
    Rx is a group of formula






    Ry is NH and
    Rz is CH3; or
    Rx is —SCH3 
    Ry is a group of formula






and

    Rz is hydrogen, or
    Rx is a group of formula






    Ry is N—CH3 and
    Rz is hydrogen; or
    Rx is the group






    Ry is N—C2H5 and
    Rz is hydrogen; or
    Rx is the group






    Ry is oxygen and
    Rz is hydrogen.


Compounds of formulae VI are partially new and may be obtained analogously to conventional methods, or, as described in the examples.
In another aspect the present invention provides a compound of formula




wherein

    R1 is as defined in formula I and
    Rxx denotes the group






wherein

    Rx, Ry and Rz as defined above.


In this specification unless otherwise indicated terms such as “compound of formula I, IA, Is, Ip, Iq, IVi, IVa and VIa” embrace the compound in any form, for example in salt form and free base form. The present invention thus includes a compound in free or base form or, where such forms exist, in salt form, for example in form of an acid addition salt, inner salt, quaternary salt and/or in solvate, for example hydrate form thereof. A salt may be a pharmaceutically acceptable salt of a compound of formulae I, IA, Is, Ip, Iq such as a metal salt or an amine salt. Metal salts include for example sodium, potassium, calcium, barium, zinc, aluminum salts, preferably sodium or potassium salts. Amine salts include for example trialkylamine, procaine, dibenzylamine and benzylamine salts. A free form of a compound of formulae I, IA, Is, Ip, Iq, IVi, IVa and VIa may be converted into a salt form and vice versa.
In a further aspect the present invention provides a compound of formulae I, IA, Is, Ip, Iq, IVi, IVa and VIa in free form; or in salt form, for example in acid addition salt form or in metal salt form; and a compound of formulae I, IA, Is, Ip, Iq, IVi, IVa and VIa in solvate form.
A compound of formula I may also be obtained analogously to other processes conventional in the β-lactam chemistry.
The compounds of formula I, hereinafter designated as “active compound(s) of the invention” exhibits pharmacological activity and are therefore useful as pharmaceuticals. In particular, the active compounds of the invention show antimicrobial, e.g. antibacterial, activity against gram negative and gram positive bacteria such as Pseudomonas, e.g. Pseudomonas aeruginosa, Pseudomonas fluorescens; Enterobacter, e.g. Enterobacter cloacae; Enterococcus, e.g. Enterococcus faecalis; Moraxella, e.g. Moraxella catarrhalis; Haemophilus, e.g. Haemophilus influenza; Klebsiella, e.g. Klebsiella edwardsii, Klebsiella pneumoniae; Streptococcus, e.g. Streptococcus pneumoniae, Streptococcus durans, Streptococcus faecium, Streptococcus pyogenes; Staphylococcus, e.g. Staphylococcus aureus, Staphylococcus pyogenes; Escherichia, e.g. Escherichia coli; and Proteus, e.g. Proteus mirabilis in vitro in the Agar Dilution Test according to National Commitee for Clinical Laboratory Standards (NCCLS) 1993, Document M7-A3Vol. 13, No. 25: “Methods for dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically—Third Edition, Approved Standard” and in vivo in the septikaemic mouse model. The active compounds of the invention show activity in the mouse when administerd at dosages from about 0.05 to 50 mg/kg body weight (ED50 values).The active compounds show an MHK(μg/ml) in the Agar Dilution Test from about 0.005 to ca. 50. The active compounds of the invention show an surprising overall activity spectrum.
It has, for example, been determined that the MHK (μg/ml) ot the compound of Example 139 against, for example Enteroccccus faecalis strains ATTC 29212 or ATCC 51299, is of ca. 0.08 to 0.25; ainst Staphylococcus aureus strains ATCC 29213 or ATCC 9144 is of ca. 0.2 to 0.4 and against Pseudomonas aeruginosa strain 27853 is ca. 0.8.
The active compounds of the invention are, therefore, useful for the treatment of microbial, e.g. bacterial diseases.
In another aspect the present invention provides a compound of claim 1 for use as a pharmaceutical, preferably as an antimicrobial agent, such as an antibiotic.
In a further aspect the present invention provides a compound of claim 1 for use in the preparation of a medicament for the treatment of microbial diseases, for example of diseaeses caused by bacterias selected from Pseudomonas, Enterobacter, Enterococcus, Moraxella, Haemophilus, Klebsiella, Streptococcus, Staphylococcus, Escherichia, and Proteus. 
In a further aspect the present invention provides a method of treatment of microbial diseases which comprises administering to a subject in need of such treatment an effective amount of a compound of formula I.
For this indication, the appropriate dosage will, of course, vary depending upon, for example, the compound of formula I employed, the host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger mammals, for example humans, an indicated daily dosage is in the range from about 0.05 to 5 g, for example 0.1 to about 2.5 g, of an active compound of the invention conveniently administered, for example, in divided doses up to four times a day.
An active compound of the invention may be administered by any conventional route, for example orally, e.g. in form of tablets or capsules, or parenterally in the form of injectable solutions or suspensions, e.g. in analogous manner to cefotaxime.
The compound 7-[[(5-Amino-1,2,4-thiadiazol-3-yl)-(Z)-(fluormethoxyimino)acetyl]amino]-3-[[(piperazinoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (compound of Example 139) is the preferred compound of the invention for use as an antimicrobial agent.
It has, for example been determined that the MHK (μg/ml) of the compound of Example 139 (tested in form of the trihydrochloride) against, for example Streptococcus pneumoniae, strain ATCC 49619 is ca. 0.01 whereas, for example ceftriaxone shows an MHK (μg/ml) of ca. 0.02. It is therefore, indicated that for the treatment of microbial diseases, e.g. bacterial diseases the preferred compounds of the invention may be administered to larger mammals, for example humans, by similar modes of administration at similar dosages than conventionally employed with ceftriaxone.
The compounds of formula I may be administered in pharmaceutically acceptable salt form, e.g. acid addition salt form or base addition salt form or in the corresponding free forms, optionally in solvate form. Such salts exhibit the same order of activity as the free forms.
The present invention also provides pharmaceutical compositions comprising a compound of formula I in pharmaceutically acceptable salt form or free form in association with at least one pharmaceutical carrier or diluent.
Such compositions may be manufactured in conventional manner.
Unit dosage form may contain, for example 10 mg to about 1 g, for example 10 mg to about 700 mg.
In the following Examples the temperatures indicated are in degree Celsius.


EXAMPLE 1
Dihydrochloride of 7-[(2-Amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[[(aminoimino-methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (Process a)
1.24 g of the hydrogen carbonate of aminoguanidine are dissolved in 9.15 ml of 2 N HCl and added under stirring to a solution of 3.2 g of the trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,39-thiazin-6-yl)-2-(2-aminothiazol-4yl)-(Z)-2-methoxyimino acetic acid amide in 125 ml of 4% aqueous acetonitrile. After ca. 90 minutes the precipitated dihydrochloride of 7-[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino-3-[[(aminoimino-methyl)-hydrazono]methyl]-3-cephem-4-carboxylic acid is filtered off, washed with acetonitrile and dried.
EXAMPLE 2
Dihydrochloride of 7-[[(2-Amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]amino]-3-[[(amino-iminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (Process a)


    a) 10 g of the hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(acetoxyimino)-acetic acid amide are suspended in 160 ml of acetonitrile and treated with 53 ml of water and 11 ml of 8 N HCl. The reaction mixture is stirred for ca. 14 hours at room temperature. A clear solution is obtained in which the acetoxyimino group being hydrolyzed to give the hydroxyimino group.
    b) 3 g of the hydrogen carbonate of aminoguanidine are dissolved in 11 ml of 1 N HCl and added dropwise to the solution obtained in step a) which is cooled to 0°. After ca. 30 minutes the reaction mixture is warmed to room temperature and stirred for ca. another 2.5 hours. The dihydrochloride of 7-[[(2-Amino-4-thiazolyl)-(Z)-(hydroxyimino)acetyl]amino]-3-[[(amino-iminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid precipitate, is filtered off, washed with a mixture of acetonitrile and water, acetonitrile and with ether and dried.


EXAMPLE 3
Sodium Salt of 7-[(2-Amino-4-thiazolyl)(methoxyimino)acetyl]amino-3-[(methoxy-imino)methyl]-3-cephem-4-carboxylic acid (Process b)
0.5 g of 7-amino-3-[(methoxyimino)methyl]-3-cephem-4-carboxylic acid and 0.75 g of (2-amino-4-thiazolyl)(methoxyimino)acetic acid mercaptobenzthiazolyl ester are suspended in a mixture of 2.4 ml of water and 4.8 ml of acetone. Ca. 1.8 ml of 2N sodium hydroxide solution are added dropwise in such a way that a pH of 8.0 is kept. The reaction mixture is stirred at 20° for ca. 1 hour. 2.4 ml of acetone are added dropwise. A clear solution is obtained within 3 hours. 120 ml of acetone are slowly added. A suspension is obtained which is cooled to 0°. After ca. 5 hours the precipitate formed is filtered off and redissolved in 4 ml of water. The clear solution is treated with 0.2 g of active charcoal and stirred for ca. 15 minutes. Active charcoal is filtered off and 100 ml of acetone are added within ca. 1 hour at 0°. The sodium salt of 7-[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino-3-[(methoxy-imino)methyl]-3-cephem-4-carboxylic acid is obtained in form of colourless crystals, which are filtered off, washed with ca. 5 ml of acetone and dried.
The compounds of the following TABLE 1 of formula IA (V is ═N—O— in all of the Examples; and W is CH in Examples 4 to 68 and 70 to 138; and W is N in Examples 69 and 139 of TABLE 1) may be obtained in analogous manner to that described in Examples 1 to 3. Salt forms are exemplified. The configuration of R3 in group —C═N—R3 is syn [(Z)].











TABLE 1





Example
R3
R2
R1
Salt



















4
CH3
OH
H
—


 


5
—CH2COOH




H
2HCl


 


6
CH3
—OCH2COONa
Na
—


7
CH3
—NH—CO—NH2
H
—


 


8
CH3




H
2HCl


 


9
CH3
—NH—C6H5
H
—


 


10
COCH3




H
2HCl


 


11
CH3




H
2HCl


 


12
CH3




H
2HCl


 


13
CH3




H
2HCl


 


14
CH3




H
2HCl


 


15
CH3




H
2HCl


 


16
H




H
2HCl


 


17
H




H
2HCl


 


18
H




H
2HCl


 


19
H




H
2HCl


 


20
CH3
—NH—CS—NH2
H
2HCl


 


21
CH3




H
HCl


 


22
CH3




H
HCl


 


23
CH3




H
HCl


 


24
CH3




H
2HCl


 


25
CH3




H
2HCl


 


26
CH3




H
2HCl


 


27
CH3




H
2HCl


 


28
CH3




H
HCl


 


29
CH3




H
2HCl


 


30
CH3




H
2HCl


 


31
CH3




H
2HCl


 


32
CH3




H
2HCl


 


33
CH3




H
2HCl


 


34
CH3




H
Cl−


 


35
CH3




H
2HCl


 


36
CH3




H
2HCl


 


37
CH3




H
2HCl


 


38
CH3




H
2HCl


 


39
CH3




H
2HCl


 


40
CH3




H
2HCl


 


41
CH3




H
HCl


 


42
CH3




H
3HCl


 


43
CH3




H
2HCl


 


44
CH3




H
HCl


 


45
CH3




H
2HCl


 


46
CH3




H
3HCl


 


47
CH3




H
2HCl


 


48
CH3




H
2HCl


 


49
CH3




H
HCl


 


50
CH3




H
2HCl


 


51
CH3




H
Cl−


 


52
CH3




H
HCl


 


53
CH3




H
2HCl


 


54
CH3




H
2HCl


 


55
CH3




H
2HCl


 


56
CH3




H
HCl


 


57
CH3




H
2HCl


 


58
CH3




H
2HCl


 


59
CH3




H
2HCl


 


60
CH3




H
2HCl


 


61
CH3




H
HCl


 


62
CH3




H
CI−2HCl


 


63
CH3




H
Cl−2HCl


 


64
CH3




H
HCl


 


65
CH3




H
HCl


 


66
CH3




H
3HCl


 


67
CH3




H
2HCl


 


68
CH3




H
2HCl


 


69
CH2F




H
2HCl


 


70
H




H
2HCl


 


71
H




H
HCl


 


72
H




H
HCl


 


73
H




H
2HCl


 


74
H




H
2HCl


 


75
H




H
2HCl


 


76
H




H
2HCl


 


77
H
OCH3
H
HCl


 


78
H




H
2HCl


 


79
H




H
2HCl


 


80
H




H
2HCl


 


81
H




H
2HCl


 


82
H




H
2HCl


 


83
H




H
2HCl


 


84
H




H
2HCl


 


85
H




H
2HCl


 


86
H




H
2HCl


 


87
H




H
2HCl


 


88
H




H
HCl


 


89
H




H
HCl


 


90
H




H
2HCl


 


91
H




H
HCl


 


92








H
2HCl


 


93
H




H
2HCl


 


94
H




H
2HCl


 


95
H




H
2HCl


 


96
H




H
3HCl


 


97
H




H
2HCl


 


98
H




H
2HCl


 


99
H




H
2HCl


 


100
H
—NH—CH═NH
H
2HCl


101
CH3
—NH—CH═NH
H
2HCl


 


102








H
2HCl


 


103








H
2HCl


 


104








H
2HCl


 


105








H
2HCl


 


106








H
2HCl


 


107








H
2HCl


 


108
CH3




H
2HCl


 


109
CH2COOH




H
2HCl


 


110
CH2COOH




H
2HCl


 


111
CH2COOH




H
2HCl


 


112
H




H
2HCl


 


113
H




H
2HCl


 


114
H




H
2HCl


 


115
H




H
2HCl


 


116
H




H
3HCl


 


117
H




H
CI−2HCl


 


118
H




H
2HCl


 


119
H




H
2HCl


 


120
H




H
2HCl


 


121
H




H
CI−2HCl


 


122
H




H
3HCl


 


123
H




H
2HCl


 


124
H




H
2HCl


 


125
H




H
3HCl


 


126
H




H
3HCl


 


127
H




H
3HCl


 


128
H




H
3HCl


 


129
CH3




H
HCl


 


130
CH3




H
HCl


 


131
CH3




H
2HCl


 


132
CH3




H
2HCl


 


133
CH3




H
—


 


134
H




H
HCl


 


135
H




H
HCl


 


136
CH3




H
2HCl


 


137
CH3




H
HCl


 


138
CH3
—NH—COC(CH3)3
H
HCl


 


139
CH2F




H
3HCl









EXAMPLE 140
Dihydrochloride of 7-[2-(2-aminothiazol-4-yl)-(Z)-2-pentenoylamino]-3-[[(aminoimino-methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid
1 g of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-[2-(tert.-butoxycarbonylamino)thiazol-4-yl]-(Z)-2-pentenoic acid amide is dissolved in a mixture of 30 ml of methanol and 30 ml of acetonitrile and 0.3 g of the hydrogencarbonate of aminoguanidine are added. A pH of 2.0 is adjusted by addition of methanolic HCl. Stirring is continued at room temperature. Within ca. 30 minutes a light coloured precipitate forms, which is filtered off after ca. 3 hours, washed with acetonitrile and ether and dried. The dihydrochloride of 7-[2-(2-aminothiazol4-yl)-(Z)-2-pentenoylamino]-3-{[(aminoimino-methyl)hydrazono]-methyl}-3-cephem-4-carboxylic acid is obtained in the form of a light yellow powder.
EXAMPLE 141
Trifluoroacetate of 7-[(2-Amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-(hydrazonomethyl)-3-cephem-4-carboxylic acid
A suspension of 3 g of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[[2-(1,1-dimethylethoxy)-2-oxoethoxy]hydrazonomethyl]-3-cephem-4-carboxylic acid in 75 ml of methylenchloride is treated at ca. 0° with 0,6 ml of anisol. 10 ml of trifluoro acetic acid are added dropwise under stirring. The solution obtained is stirred for ca. further 3 hours at 0°. The reaction mixture is poured into 600 ml of ether. The trifluoroacetate of 7-[(2-Amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]-amino-3-(hydrazono)-3-cephem-4-carboxylic acid precipitates, is filtered off and dried.
EXAMPLE 142
Hydrobromide of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(4-methylthiazol-2-yl)hydrazonomethyl]-3-cephem-4-carboxylic acid
1 g of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(aminothioxome-thyl)-hydrazonomethyl]-3-cephem-4-carboxylic acid is suspended in 30 ml of acetonitrile and stirred after addition of 2.5 ml of N,O-bistrimethylsilylacetamide for ca. 20 minutes. The clear solution obtained is treated with 0.6 g of bromoacetone and stirred overnight. 1 ml of water are added. The precipitate is filtered off and dried. The hydrobromide of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(4-methylthiazol-2-yl)hydrazonomethyl]-3-cephem-4-carboxylic acid is obtained as a yellow solid.
EXAMPLE 143
Hydrobromide of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(4-methylthiazol-2-yl)methylhydrazonomethyl]-3-cephem-4-carboxylic acid
1 g of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)acetyl]amino-3-[(aminothioxome-thyl)-methylhydrazonomethyl]-3-cephem-4-carboxylic acid is reacted in analogous manner as described in Example 142 with N,O-bistrimethylsilylacetamide and with bromoacetone. The hydrobromide of 7-[(2-amino-4-thiazolyl)-(Z)-(methoxyimino)-acetyl]amino-3-[(4-methylthiazol-2-yl)methylhydrazonomethyl]-3-cephem-4-carboxylic acid is obtained as a yellow solid.
EXAMPLE 144
Dihydrate of 6R-trans (Z)-7-[(2-Amino-4-thiazolyl)(methoxyimino)-acetyl]amino-3[[(imino(methylamino)methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid
1.1 g of the dihydrochloride obtained according to Example 8 are dissolved in 25 ml of water, treated with 0.5 g of active charcoal and stirred for ca. 5 minutes. The almost colourless filtrate is poured into 5 ml of water under stirring. A pH of about 7 is kept by addition of 2.5% aqueous ammonia. The precipitate obtained is filtered off and dried. The dihydrate of 6R-trans (Z)-7-[(2-Amino-4-thiazolyl)-(methoxyimino)-acetyl]amino-3[[(imino(methylamino)methyl)hydrazono]-methyl]-3-cephem-4-carboxylic acid is obtained as a yellowish powder.
EXAMPLE 145
6R-trans (Z)-7-[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino-3-[[(imino(methylamino)methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester
5.5 g of the dihydrate obtained according to Example 144 are dissolved in 55 ml of dimethylacetamide under addition of 1.43 ml tetramethylguanidine. This solution is cooled to 0°, treated with a solution of 4.4 g of 1-iodoethyl-isopropylcarbonate in 30 ml of toluene and stirred for ca. 90 minutes at 0°. The reaction mixture is poured into 1 liter of diethylether. The precipitate obtained is filtered off and stirred twice each with 500 ml of acetonitrile. The acetonitrile phases are combined, filtered and evaporated to a volume of ca. 10 ml. The oily residue is treated with 400 ml of water. A precipitate forms which is filtered off and dried. The precipitate is stirred with 700 ml of ethyl acetate. After evaporation of the ethyl acetate yellow coloured 6R-trans (Z)-7-[(2-amino-4-thiazolyl)-(methoxyimino)acetyl]amino-3-[[(imino(methylamino)methyl)hydrazono]methyl]-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester is obtained in the form of a diastereomeric mixture in the ratio of ca. 1:1.
EXAMPLE 146
6R-trans (Z)-7-[((Acetoxyimino)-2-amino-4-thiazolyl)acetyl]amino-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester
0,72 g of the hydrogen carbonate of aminoguanidine are dissolved in 5.2 ml of 2 N HCl. This solution is added to a solution of 2 g of 6R-trans (Z)-7-[((acetoxyimino)-2-amino-4-thiazolyl)acetyl]amino-3-formyl-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy)ethyl ester in 14 ml of acetonitrile containing 1.3 ml of water. The reaction mixture is stirred for ca. 45 minutes at room temperature and poured into 100 ml of acetonitrile. The precipitate formed is filtered off and dissolved in 100 ml of water. The pH of the solution obtained is adjusted to 7 by addition of 0.5 N aqueous sodium hydrogen carbonate. A yellow suspension is obtained which is extracted twice with a mixture of 200 ml of ethyl acetate and 40 ml of acetonitrile. The organic phases are combined, dried over Na2SO4 and evaporated. 6R-trans (Z)-7-[((acetoxyimino)-2-amino-4-thiazolyl)acetyl]amino-3-[[(aminoiminomethyl)hydrazono]-methyl]-3-cephem-4-carboxylic acid 1-(isopropoxycarbonyloxy) ethyl ester is obtained in the form of a yellow diastereomeric mixture in the ratio of ca. 1:1.
EXAMPLE 147
Ditosylate of 6R-trans (Z)-7-[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (isopropoxycarbonyloxy)ethyl ester
A solution of 0.6 g of a compound obtained according to Example 146 in a mixture of 50 ml of acetonitrile and 20 ml of isopropanol is treated with 0.66 g of the monohydrate of toluene-4-sulfonic acid and stirred overnight at 25°. The reaction mixture is poured into 150 ml of tert.butyl-methylether. The precipitate obtained is filtered off, washed with tert.butyl-methylether and dried. The ditosylate of 6R-trans (Z)-7-[(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino-3[[(aminoiminomethyl)-hydrazono]methyl]-3-cephem-4-carboxylic acid (isopropoxycarbonyloxy)ethyl ester is obtained in the form of a light coloured diastereomeric mixture in the ratio of ca. 1:1.
EXAMPLE 148
Dihydrochloride of 7-[[(2-amino-4 thiazolyl)-(Z)-[(carboxymethoxy)imino]actyl]-amino]-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid (Compound of Example 5)
a) Dihydrochloride of 7-Amino-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid
To 1.0 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid in a mixture of 50 ml of acetonitrile and 5 ml of 2N HCl are added dropwise 0.6 g of the hydrogen carbonate of aminoguanidine, dissolved in 2.2 ml of 2N HCl. The dihydrochloride of 7-amino-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid precipitates, is filtered off, washed with acetonitrile and dried.
b) Hydrochloride of 7-[[(2-amino-4-thiazolyl)-(Z)-[[2-(1,1-dimethylethoxy)-2-oxoetoxy]imino]acetyl]amino]-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid
4 g of the dihydrochloride of 7-amino-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid are dissolved in 80 ml of methanol. The solution is cooled to 0° and treated with a solution of 7 g of (2-amino-4-thiazolyl)-(Z)-[2-(1,1-dimethylethoxy)-2-oxoethoxy]imino]thioacetic acid S-benzothiazol ester in 50 ml of methylene chloride. The reaction mixture is stirred for about 2.5 hours at 20°. About a third of the solvent is evaporated off and 120 ml of ether are added to the residue. The hydrochloride of 7-[[(2-amino-4-thiazolyl)-(Z)-[[2-(1,1-dimethylethoxy)-2-oxoetoxy]imino]-acetyl]amino]-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid precipitates, is filtered off, washed with ether and dried.
c) Dihydrochloride of 7-[[(2-amino-4 thiazolyl)-(Z)-[(carboxymethoxy)imino]actyl]-amino]-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid
3.5 g of the hydrochloride of 7-[[(2-amino-4-thiazolyl)-(Z)-[[2-(1,1-dimethylethoxy)-2-oxoetoxy]imino]acetyl]amino]-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid are dissolved in 20 ml of trifluoroacetic acid at 0°. The solution is stirred for ca. 15 minutes at 0° and for ca. 1 hour at 20°. The reaction mixture is treated with 40 ml of ether. A precipitate forms, is filtered off, washed with ether, dried, dissolved in 15 ml of 2N HCl and stirred for ca. 1 hour at 20°. A light brownish precipitate of the dihydrochloride of 7-[[(2-amino-4 thiazolyl)-(Z)-[(carboxy-methoxy)imino]actyl]-amino]-3-[[(aminoiminomethyl)hydrazono]methyl]-3-cephem-4-carboxylic acid is obtained, filtered off and dried.
The compounds of Examples 1 to 146 may be obtained as described in Example 147 using the appropriate starting material.
Compounds used as starting material may be prepared as follows:
EXAMPLE A)
Trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetic acid amide
a) Hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-ace-to [2,1-b]furo[3,4-d][1,3]thiazin (hydroxylactone of the hydrochloride of 7-amino-3-formyl-3-cephem-4-carboxylic acid)
13.8 g of the hydrochloride of 7-amino-3-[(Z/E)-prop-1-en-1-yl]-3-cephem-4-carboxylic acid are dissolved in 200 ml of methanol. The solution is cooled to −50° and 8 l O2 containing ca. 2 percent v/v ozone are introduced per minute under stirring at this temperature. After ca. 20 minutes the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-aceto[2,1-b]furo[3,4-d][1,3]thiazin being practically quantitatively formed and ozonolysis is terminated as determined by HPLC. 8 l N2 are bubbled through the reaction mixture within ca. 2 minutes. The slight cloudy solution is poured into 1400 ml of tert.butyl-methyl ether. The precipitate is filtered off under N2, washed with a little of tert.butyl-methyl ether and acetonitrile and dried. The hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-aceto[2,1-b]furo[3,4-d][1,3]thiazin is obtained in the form of a white powder (HPLC content of more than 95%).
b) (6R-trans)-7-Amino-3-formyl-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-en-2-carboxylic acid (7-amino-3-formyl-3-cephem-4-carboxylic acid)
2.64 g of the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-aceto[2,1-b]furo[3,4-d][1,3]thiazin are dissolved in 50 ml of methanol. To this solution a solution of 0.78 g of pyridin in 10 ml of methanol is added dropwise under ice cooling and stirring. The precipitate obtained is filtered off moisture free under nitrogen, washed with a little methanol and dried. (6R-trans)-7-Amino-3-formyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid is obtained in the form of a light brownish powder.
IR (KBr): 1799 cm−1 (β-lactam), 1672 cm−1 (CHO), 1606 and 1542 cm−1 (carboxylate) UV-Spectrum: λmax in H2O=302 nm.
c) N-(1,4,5a,6-Tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-tritylaminothiazol-4-y)-(Z)-2-methoxyiminoacetic acid amide
10 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid in 200 ml of acetonitrile: methylenchloride (1:1) are treated with 37.4 ml of N,O-bis(trimethylsilyl)acetamide at room temperature within ca. 5 minutes. After ca. 30 minutes the reaction mixture is cooled to −10° and 21 g of 2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyiminoacetic acid chloride are added in 3 portions. The temperature raises to −5°. After ca. 45 minutes the reaction mixture is treated with 4 ml of water. The temperature raises to 20°. The reaction mixture is stirred for ca. 10 minutes and filtered. 15 g of active charcoal are added to this filtrate and stirring is continued for ca. 10 minutes. After filtration the solvent of the filtrate obtained is evaporated. The evaporation residue is treated with tert.butyl-methyl ether. A crystalline, almost colourless precipitate is obtained, filtered off and dried. Crystalline N-(1,4,5a,6-Tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-tritylaminothiazol-4-yl)-2-methoxyiminoacetic acid amide is obtained in form of a diastereomeric mixture in the ratio of ca. 1:1.
d) Trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1 .7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetic acid amide
5 g of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid amide are introduced into 20 ml of trifluoro acetic acid at 0°. The temperature raises to 10°. The reaction mixture is stirred for ca. 30 minutes at 0° and added dropwise into 200 ml of diethylether. The mixture obtained is stirred for ca. 5 minutes and filtered. A crystalline, diastereomeric mixture of the trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid amide in the ratio of ca. 1:1 is obtained.
EXAMPLE B)
Trifluoroacetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6yl)-(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetic acid amide
is obtained in form of a light yellow powder analogously as described in Example A) c) to d) but using in step c) 2-(2-tritylaminothiazol4-yl)-(Z)-2-hydroxyimino acetic acid chloride instead of 2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyimino-acetic acid chloride.
EXAMPLE C)
Hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoro-methoxyimino)acetic acid amide
A suspension of 3.73 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid in a mixture of 80 ml of methylenchloride and 30 ml of acetonitrile is stirred at 0° with 16 ml of N,O-bis(trimethylsilylacetamide). Within ca.15 minutes a clear solution is obtained to which 3.9 g of (5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-fluormethoxyiminoacetic acid chloride, obtainable for example as described in Example 1 of EP-0 590 681, are added. The reaction mixture is stirred for ca. 1 hour at 0°. 500 ml of acetonitrile containing 10 g of water are added and the mixture is filtered to remove insolubles. The filtrate is evaporated. The residue is treated with 500 ml of acetonitrile, the mixture is filtered and the filtrate is evaporated. The solid obtained is treated with tert.butyl-methyl ether and dried. The hydrochloride of N-(1,4,5a,6-Tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-(fluoro-methoxyimino)acetic acid amide is obtained in the form of a light brownish powder.
EXAMPLE D)
Hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(acetoxyimino)acetic acid amide
40 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid are suspended in 1500 ml of acetonitrile and cooled to 0°. Within ca. 20 minutes 170 ml of N,O-bis(trimethylsilyl)acetamide are added under stirring. Within ca.15 minutes at 0° a clear solution is obtained, which is cooled to −10° and to which 48 g of (2-aminothiazol-4-yl)-(Z)-(acetoxyimino)acetic acid chloride are added in portions in such a way that the temperature of the reaction mixture does not exceed −8°. Stirring is continued for ca. 60 minutes at −10° and 168 ml of water are added. Stirring is continued for ca. further 20 minutes at 0° and for ca. 2 hours at room temperature. A crystalline precipitate forms, is filtered off, washed with ca. 350 ml of acetonitrile and ca. 100 ml of ether and dried. The hydrochloride of N-(1,4,5a,6-tetra-hydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo-[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(acetoxyimino)acetic acid is obtained in form of a diastereomeric mixture in the ratio of ca. 1:1.
EXAMPLE E)
Hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(hydroxyimino)acetic acid amide
10 g of the hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl)-2-(2-aminothiazol4-yl)-(Z)-2-(acetoxyimino)-acetic acid amide are suspended in 160 ml of acetonitrile and treated with 53 ml of water and 11 ml of 8 N HCl. The reaction mixture is stirred for ca. 14 hours at room temperature. A clear solution is obtained which is diluted with water-free acetonitrile to obtain the 3-fold volume. The solvent is evaporated off to obtain a volume of ca. 10 ml, which is treated with ca. 200 ml of acetonitrile. A precipitate forms which is treated with ether, filtered off and dried. The hydrochloride of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-(hydroxyimino)acetic acid amide is obtained in yellowish coloured form.
EXAMPLE F)
Trifluoracetate of N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3-]-thiazin-6-yl)-2-(2-aminothiazol-4-yl)-(Z)-2-[(1-carboxy-1-methylethoxy)imino]acetic acid amide
is obtained in form of a light brownish powder analogously as described in Example A) a) to c) but using 2-(2-tritylaminothiazol-4-yl)-(Z)-2-[(1-carboxy-1-methylethoxy)-iminoacetic acid chloride instead of 2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyimino-acetic acid chloride.
EXAMPLE G)
N-(1,4,5a,6-Tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]-thiazin-6-yl)-2-[2-(tert.-butoxycarbonylamino)thiazol-4-yl]-(Z)-2-pentenoic acid amide
is obtained in form of a light brownish powder analogously as described in Example A) c) to d) but using 2-(2-(tert.butoxycarbonylamino)thiazol-4-yl)-(Z)-2-pentenoic acid chloride instead of 2-(2-tritylaminothiazol-4-yl)-(Z)-2-methoxyimino-acetic acid chloride.
EXAMPLE H)
Dihydrochloride of 1-(hydrazinoiminomethyl)piperazine
a) Hydroiodide of 4-formyl-1-[imino(methylthio)methyl]piperazine
25.5 g of 4-formyl-1-piperazinecarbothioamide are suspended in 80 ml of methanol, treated with 22 g of methyliodide and refluxed. Within ca. 10 minutes a clear solution is obtained. The mixture is cooled to room temperature. The solvent is evaporated. Crystalline hydroiodide of 4-formyl-1-[imino(methylthio)methyl]piperazine is obtained.
b) Hydrochloride of 4-formyl-1-(hydrazinoiminomethyl)piperazine
48.1 g of the hydroiodide of 4-formyl-1-[imino(methylthio)methyl]piperazine are dissolved in 100 ml of water, run through a column filled with 800 ml of a strong basic ion exchanger in chloride form and eluated with 850 ml of water. The solvent is evaporated to obtain a volume of ca. 100 ml which is treated with 7.35 g of hydrazinehydrate. The reaction mixture is stirred for ca. 1 hour at room temperature and the solvent is evaporated off. The oily hydrochloride of 4-formyl-1-(hydrazinoiminomethyl)piperazine crystallizes on drying.
c) Dihydrochloride of 1-(hydrazinoiminomethyl)piperazine
11 g of the hydrochloride of 4-formyl-1-(hydrazinoiminomethyl)piperazine are dissolved in 400 ml of methanol and treated with 50 of HClconc. The reaction mixture is stirred for ca. 14 hours at room temperature. A white precipitate forms, is filtered off, washed with methanol and ether, dried and recrystallized with water/ethanol. The dihydrochloride of 1-(hydrazinoiminomethyl)-piperazine is obtained in crystalline, colourless form.
Analogous in the manner as described in Example H) compounds of formula IV of TABLE 2 may be obtained:










TABLE 2





Ex.
R2
Salt
Process







I)




HCl
H) a) to c)


 


J)




HCl
H) a) to c)


 


K)




HCl
H) a) to c)


 


L)




2HCl
H) a) to c)


 


M)




2HCL
H) a) to c)


 


N)




HCl
H) a) to b)


 


O)




3HCl
H) c)









EXAMPLE P)
1-Amino-3-(2-hydroxyethyl)-4-methylguanidine
12.7 g of 2-methylamino-2-oxazoline ar dissolved in 50 ml of water, treated with 3 g of hydrazinehydrate and stirred for ca. 17 hours at room temperature. The solvent is evaporated and 1-amino-3-(2-hydroxyethyl)-4-methylguanidine is obtained as oily residue crystallizing upon cooling.
EXAMPLE Q)
Hydrochloride of 1,1-dimethyl-4-(hydrazinoiminomethyl)piperaziniumchloride
a) Hydroiodide of 1,1-dimethyl-4-[imino(methylthio)methyl]piperaziniumiodide
3.2 g of 4-methyl-1-piperazinecarbothioamide are suspended in 100 ml of methanol. 6.2 g of methyliodide are added and the mixture is refluxed for ca. 2 hours and cooled to 20° ab. The hydroiodide of 1,1-dimethyl-4-[imino-(methylthio)methyl]piperaziniumiodide precipitates, is filtered off and dried.
b) Hydrochloride of 1,1-dimethyl-4-(hydrazinoiminomethyl)piperaziniumchloride
6.57 g of the hydroiodide of 1,1-dimethyl-4-[imino(methylthio)methyl]piperaziniumiodide are dissolved in 70 ml of water, run through a column filled with 150 ml of a strong basic ion exchanger in chloride form and eluated with 250 ml of water. Water is evaporated off the eluate to obtain to a volume of ca. 50 ml, which is treated with 0.9 ml of hydrazinehydrate and stirred overnight. The solvent is evaporated off and the residue obtained is treated with n-hexane. The hydrochloride of 1,1-dimethyl-4-(hydrazinoiminomethyl)piperaziniumchloride is obtained.
EXAMPLE R)
Trihydrochloride of 1-[hydrazino(methylimino)methyl]piperazine
a) Hydrochloride of S-methyl-2-methylisothiosemicarbazide
A solution of 239.8 g of the hydroiodide of S-Methyl-2-methylisothiosemicarbazide in 100 ml of water is run through a column filled with 1500 ml of a strong basic ion exchanger in chloride form and eluated with water. The eluate is lyophilized and the lyophilization residue is treated with ether. The precipitate is filtered off and dried. The hydrochloride of S-methyl-2-methylisothiosemicarbazide is obtained as a white solid.
Melting point: 116°
b) Hydrochloride of 4-formyl-1-[hydrazino(methylimino)methyl]piperazine
A mixture of 20 g of freshly distilled formylpiperazine and 27.3 g of the hydrochloride of S-methyl-2-methylisothiosemicarbazide in 250 ml of ethanol is refluxed overnight and the solvent is evaporated. The oily residue is dissolved in 70 ml of hot isopropanol and the solution is slowly cooled to 20°. A precipitate forms and the mixture is allowed to stand for ca. 2 hours at 4°. The hydrochloride of 4-formyl-1-[hydrazino(methylimino)methyl]piperazine is filtered off and recrystallized from isopropanol.
c) Trihydrochloride of 1-[hydrazino(methylimino)methyl]piperazine
10 g of the hydrochloride of 1-formyl-4-[hydrazino(methylimino)methyl]piperazine are dissolved in 250 ml of methanol. 50 ml of HClconc. are added, the mixture obtained is stirred overnight and the solvent is evaporated. A solid residue is obtained which is dried over solid KOH. The trihydrochloride of 1-[hydrazino-(methylimino)methyl]piperazine is obtained in form of a white product.
In analogous manner as described in Example R) but reacting the hydrochloride of S-methyl-isothiosemicarbazide or the hydrochloride of S-methyl-2-methylisothiosemicarbazide or the hydrochloride of S-methyl4-methylisothiosemicarbazide with a corresponding amine compounds of formula IV of TABLE 3 may be obtained.











TABLE 3







Ex.
R2
Salt









S)




HCl



 



T)




HCl



 



U)




HCl



 



V)




2HCl










EXAMPLE W)
Hydrochloride of 1-Amino-3-(3,4-dihydroxybenzylidenamino)guanidine
1 g of the hydrochloride of diaminoguanidine are dissolved in 10 ml of 4 N HCl and diluted with 20 ml of methanol. This solution is treated quickly with a solution of 1 g of 3,4-dihydroxybenzaldehyde in 40 ml of methanol. The reaction mixture is stirred for some minutes at room temperature and the solvent is evaporated off. The residue is suspended in 50 ml of acetonitrile. The precipitate formed is filtered off and dried. The hydrochloride of 1-amino-3-(3,4-dihydroxybenzylidenamino)-guanidine is obtained.
EXAMPLE X)
Hydroiodide of S-Methyl-4-cyclopropylthiosemicarbazide
295 mg of 4-cyclopropylthiosemicarbazide are dissolved in 5 ml of dry methanol and treated with 154 ml of methyliodide. The mixture is stirred at 40° under nitrogen for ca. 5 hours, cooled and treated with diethylether. A colourless precipitate of the hydroiodide of S-Methyl-4-cyclopropylthiosemicarbazide is formed, filtered off, washed with diethylether and dried.
EXAMPLE Y)
Hydroiodide of S-methyl-4-n-butylthiosemicarbazide
147 mg of 4-n-butylthiosemicarbazide in 2,5 ml of dry methanol are treated with 149 mg of methyliodide. The mixture is stirred under nitrogen for ca. 5 hours, cooled and treated with diethylether. A colourless precipitate of the hydroiodide of S-methyl-4-n-butylthiosemicarbazide is formed, filtered off, washed with diethylether and dried.
EXAMPLE Z)
1-Methyl-5-mercapto-1,2,4-triazol-3-carboxylic acid hydrazide
0.48 g of 1-methyl-5-mercapto-1,2,4-triazol-3-carboxylic acid methyl ester are dissolved in 10 ml of methanol, treated with 450 μl of hydrazinehydrate and stirred for ca. 2 hours at 20°. A precipitate of 1-methyl-5-mercapto-1,2,4-triazol-3-carboxylic acid hydrazide is formed, filtered off, washed with methanol and dried.
IR (KBr): 1669 cm−1, 1608 cm−1, 1517 cm−1 13C-NMR (300 MHz, DMSO-d6): 35.4 (NCH3); 143.3, 154.3 and 166.7
EXAMPLE AA)
Hydroiodide of 1,5-dimethyl-2-(hydrazinoiminomethyl)pyrrol
a) 1,5-Dimethylpyrrol-2-carbothioamide
5 g of 2cyano-1,5-dimethylpyrrol are dissolved in 40 ml of ethanol and treated with 10 ml of triethylamine. 50 ml of an ethanolic H2S solution (3.8 g/100 ml) are added and the mixture is heated for ca. 15 hours in an autoclave at 70°. The reaction mixture is cooled and the solvent is evaporated off to obtain ca. a quarter of its volume. 1,5-dimethylpyrrol-2-carbothioamide crystallizes upon cooling at 0° in the form of a light yellow precipitate.
b) Hydroiodide of 1,5-dimethyl-2-[imino(methylthio)methyl]pyrrol
1 g of 1,5-dimethylpyrrol-2-carbothioamide are dissolved in 20 ml of methanol and treated with 1.7 g of methyliodide. The reaction mixture is stirred for about 5 hours at room temperature. The solvent is evaporated until crystallization starts. The residue is cooled to ca. 0°. The crystalline hydroiodide of 1,5-dimethyl-2-[imino(methylthio)methyl]pyrrol is filtered off, washed with methanol and dried.
c) Hydroiodide of 1,5-dimethyl-2-(hydrazinoiminomethyl)pyrrol
1.3 g of the hydroiodide of 1,5-dimethyl-2-[imino(methylthio)methyl]pyrrol are dissolved in 20 ml of methanol. 0.28 g of hydrazinehydrate are added. The reaction mixture is stirred for ca. 3 hours, the solvent is evaporated off and the residue is recrystallized from acetonitrile/ether. The hydroiodide of 1,5-dimethyl-2-(hydrazinoiminomethyl)pyrrol is obtained.
EXAMPLE AB)
Hydroiodide of 3,4-dihydroxy-2-(hydrazinoiminomethyl)benzene
is obtained in analogous manner as described in Example AA), but using 3,4-dihydroxy-thiobenzamide instead of 1,5-dimethylpyrrol-2-carbothioamide.
EXAMPLE AC)
7-Amino-3-[[(carboxymethoxy)imino]methyl]-3-cephem-4-carboxylic acid
A solution of 1.86 g of the hydrochloride of aminooxyacetic acid in 20 ml of water is treated under stirring at 0° with 3.16 g of the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin. The mixture is stirred for ca. 8 hours at 0°. 7-Amino-3-[[(carboxymethoxy)imino]methyl]-3-cephem-4-carboxylic acid precipitates in form of colourless crystals, which are filtered off, washed with 5 ml of cold water and 5 ml of acetone and dried.
EXAMPLE AD)
7-Amino-3-[(methoxyimino)methyl]-3-cephem-4-carboxylic acid
A solution of 0.5 g of the hydrochloride of O-methylhydroxylamine in 10 ml of water is treated under stirring at 0° with 1.38 g of 7-amino-3-formyl-3-cephem-4-carboxylic acid and stirred for ca. 8 hours at 0°. 7-Amino-3-[(methoxyimino)methyl]-3-cephem-4-carboxylic acid precipitates in form of almost white crystals, which are filtered off, washed with 5 ml of cold water and 5 ml of acetone and dried.
EXAMPLE AE)
7-Amino-3-[(hydroxyimino)methyl]-3-cephem-4-carboxylic acid
a) A solution of 1.26 g of the hydrochloride of hydroxylamine in 7.5 ml of water is treated under stirring at 0° with 4.74 g of the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin and stirred for ca. 8 hours at 0° under nitrogen. The pH of the reaction mixture is adjusted to 3.5 using solid sodium hydrogen carbonate. 7-Amino-3-[(hydroxy-imino)methyl]-3-cephem-4-carboxylic acid precipitates in form of colourless crystals, which are filtered off, washed with ca. 5 ml of cold water and 5 ml of acetone and dried.

b) A suspension of 0.79 g of the hydrochloride of 6-amino-1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto[2,1-b]furo[3,4-d][1,3]thiazin in 10 ml of dichloromethane is treated under stirring at 4° with 2.67 g of N,O-bis-(trimethylsilyl)acetamide. A clear solution is obtained within 10 minutes. 0.21 g of the hydrochloride of hydroxylamine are added. The reaction mixture is stirred for ca. 2 hours under nitrogen at 4° and the solvent is evaporated off. The residue is treated with 10 ml of isopropylalkohol, precooled to 1°. 7-Amino-3-[(hydroxy-imino)methyl]-3-cephem-4-carboxylic acid precipitates in form of almost colourless crystals which are filtered off, washed with 5 ml of acetone and dried.

Analoguously as described in Examples AC) to AE) the compounds of Table 4 of formula VI may be obtained.










TABLE 4





Bsp:
R1
R2
Salz







AF)
H




2HCl


 


AG)
H
—NH—CO—NH2
2HCl


AH)
H
—NH—CS—NH2
2HCl


 


AI)
H




HCl


 


AJ)
H




2HCl


 


AK)
H
—NH—C6H5
H2N—NH—C6H5









1H-NMR-Spectra of the Compounds Obtained According to the Examples (Ex.)











Ex.
Spectrum







1
(300 MHz, CD3OD): 8.43(s, 1H, CH═N); 6.96(s, 1H, CH); 5.99(d,



J=4.9Hz, 1H, CH); 5.22(d, J=4.9Hz, 1H, CH); 4.04(s, 3H, OCH3);



3.99 and 3.56(AB quartet, J=17.8Hz, 2H, SCH2).


2
(90 MHz, DMSO-d6 + D2O): 3.6 and 4.3(AB quartet, J=18Hz, 2H,



SCH2); 5.3(d, J=5.1Hz, 1H, β-lactam-H); 5.95(d, J=5.1Hz, 1H,



β-lactam-H); 6.95(s, 1H, thiazolyl-H); 8.35(s, 1H, CH═N).


3
(300 MHz, CD3OD): 7.97(s, 1H, CH═N); 6.84(s, 1H, CH); 5.69(d,



J=4.9Hz, 1H, CH); 5.13(d, J=4.9Hz, 1H, CH); 4.13 and 3.93(AB



quartet, J=16.8Hz, 2H, SCH2), 3.81(s, 3H, OCH3); 3.67(s, 3H, OCH3).


4
(300 MHz, CD3OD): 8.36(s, 1H, CH═N); 6.87(s, 1H, CH); 5.88(d,



J=4.9Hz, 1H, CH); 5.29(d, J=4.9Hz, 1H, CH); 4.00(s, 3H, OCH3);



3.95 and 3.60(AB quartet, J=17.8Hz, 2H, SCH2).


5
(300 MHz, DMSO-d6): 3.57 and 4.43(AB quartet, J=18.2Hz, 2H,



S—CH2); 4.71(s, 2H, O—CH2); 5.30(d, J=5.0Hz, 1H, β-lactam-H); 5.91



(dd, J=5.0 and 7.9Hz, 1H, β-lactam-H); 7.02(s, 1H, CH thiazol); 7.9



(broad 4H, NH); 8.29(s, 1H, CH═N); 9.88(d, J=7.9Hz, 1H, NH); 12.25



(s, 1H, OH).


6
(300 MHz, CD3OD): 8.10(s, 1H, CH═N); 7.01(s, 1H, CH); 5.84(d,



J=4.9Hz, 1H, CH); 5.29(d, J=4.9Hz, 1H, CH); 3.98(s, 3H, OCH3);



3.96 and 3.59(AB quartet, J=16.8Hz, 2H, SCH2).


7
(300 MHz, CD3OD): 8.26(s, 1H, CH═N); 7.04(s, 1H, CH); 5.90(d,



J=5.1Hz, 1H, CH); 5.24(d, J=5.1Hz, 1H, CH); 4.05(s, 3H, OCH3);



4.32 and 3.65(AB quartet, J=17.8Hz, 2H, SCH2).


8
(300 MHz, CD3OD): 8.46(s, 1H, CH═N); 6.99(s, 1H, CH); 5.95(d,



J=5.2Hz, 1H, CH); 5.27(d, J=5.2Hz, 1H, CH); 4.01(s, 3H, OCH3);



4.37 and 3.63(AB quartet, J=18.1Hz, 2H, SCH2); 2.95(s, 3H, N—CH3).


9
(90 MHz, DMSO-d6): 9.78(d, J=8.0Hz, 1H, CONH); 8.26(s, 1H,



CH═N); 6.91(s, 1H, CH); 7.32(dd, J=7.3Hz, 2H, Hm); 7.05(d, J=7.3Hz,



2H, Ho); 6.78(t, J=7.3Hz, 1H, Hp); 5.76(dd, J1=4.8Hz, J2=8.0Hz,



1H, CH); 5.25(d, J=4.8Hz, 1H, CH); 3.91(s, 3H, OCH3); 4.16 and 3.76



(AB quartet, J=17.4Hz, 2H, SCH2).


10
(90 MHz, DMSO-d6): 2.25(s, 3H, CH3CO); 3.65 and 4.55(AB quartet,



J=18Hz, 2H, SCH2); 5.4(d, J=5Hz, 1H, β-lactam-H); 5.95(dd, J=5Hz



and 8Hz, 1H, β-lactam-H); 7.32(s, 1H, thiazolyl-H); 8.4(s, 1H, CH═N);



10.2(d, J=8.0Hz, 1H, NH).


11
(90 MHz, DMSO-d6): 1.12(t, J=7.1Hz, 3H, CH3); 3.29(q, 2H, CH2);



3.56 and 4.50(AB quartet, J=18.1Hz, 2H, SCH2); 3.93(s, 3H, N—O—



CH3); 5.30(d, J=5Hz, 1H, CH); 5.9(q, J=6Hz, and 8Hz, 1H, CH); 6.90



(s, 1H, thiazolyl-H); 8.32(s, 1H, CH═N); 9.86(d, J=8.0Hz, NH).


12
(90 MHz, DMSO-d6): 1.85-2.15(m, 4H); 3.25-3.7(m, 5H, —CH2—N—CH2—



and 1H of SCH2); 4.0(s, 3H, N—O—CH3); 4.5(part of the AB quartet,



J=18Hz, 1H of SCH2); 5.3(d, J=5Hz, 1H, CH); 5.9(q, J=5Hz and 8Hz,



1H, CH); 7.0(s, 1H, thiazolyl-H); 8.8(s, 1H, CH═N); 10.1(d, J=7.9Hz,



NH).


13
(90 MHz, DMSO-d6): 2.9(broad s, 6H, N—CH3), 3); 3.6 and 4.5(AB



quartet, J=18Hz, 2H, SCH2); 3.9(s, 3H, N—O—CH3); 5.3(d, J=5Hz, 1H,



CH));(q, J=5Hz and 8Hz, 1H, CH); 6.95(s, 1H, thiazolyl-H); 8.75(s,



1H, CH═N); 9.95(d, J=8Hz, NH).


14
(90 MHz, DMSO-d6): 3.65(broad s, 4H, N—CH2—CH2—N); 3.5 and 4.4(AB



quartet, J=18Hz, 2H, SCH2); 3.9(s, 3H, N—O—CH3); 5.3(d, J=5.0Hz, 1H,



CH); 5.85(q, J=5Hz and 8Hz, 1H, CH); 6.9(s, 1H, thiazolyl-H); 8.35(s,



1H, CH═N); 9.9(d, J=8Hz, NH).


15
(90 MHz, DMSO-d6): 1.16(t, J=7.1Hz, 3H, CH3); 1.8-2(m, 4H); 3.32(q,



2H, CH2); 3.45-3.65(m, 5H, —CH2—N—CH2— and 1H of SCH2); 3.91(s, 3H,



N—O—CH3); 4.1(part of the AB quartet, J=18Hz, 1H of SCH2); 5.27(d,



J=5Hz, 1H, CH); 5.9(q, J=5Hz and 8Hz, 1H, CH); 6.86(s, 1H, thiazolyl-



H); 8.56(s, 1H, CH═N); 9.82(d, J=8Hz, NH).


16
(90 MHz, DMSO-d6): 2.86(broad s, 3H, N—CH3); 3.5 and 4.5(AB



quartet, J=18Hz, 2H, SCH2); 5.3(d, J=6Hz, 1H, CH); 5.9(q, J=5Hz and



8Hz, 1H, CH); 6.85(s, 1H, thiazolyl-H); 8.4(s, 1H, CH═N); 9.8(d,



J=8Hz, NH).


17
(90 MHz, DMSO-d6): 1.85-2.15(m, 4H); 3.25-3.8(m, 5H, —CH2—N—CH2—



and 1H of SCH2); 4.5(part of the AB quartet, J=18Hz, 1H of SCH2); 5.3



(d, J=5Hz, 1H, CH); 5.85(q, J=5Hz and 8Hz, 1H, CH); 6.85(s, 1H,



thiazolyl-H); 8.7(s, 1H, CH═N); 9.8(d, J=7.9Hz, NH).


18
(90 MHz, DMSO-d6): 2.86(broad s, 6H, N—CH3), 3); 3.55 and 4.47(AB



quartet, J=18.9Hz, 2H, SCH2); 5.31(d, J=5.1Hz, 1H, CH); 5.91(q,



J=5.1Hz and 7.9Hz, 1H, CH); 6.8(s, 1H, thiazolyl-H); 8.58(s, 1H,



CH═N); 9.72(d, J=7.9Hz, NH).


19
(90 MHz, DMSO-d6): 3.7(broad s, 4H, N—CH2—CH2—N); 3.55 and 4.35



(AB quartet, J=18.1Hz, 2H, SCH2); 5.31(d, J=5.0Hz, 1H, CH); 5.9(q,



J=5.1Hz and 8Hz, 1H, CH); 6.8(s, 1H, thiazolyl-H); 8.38(s, 1H, CH═N);



9.73(d, J=8.0Hz, NH).


20
(300 MHz, CD3OD): 8.34(s, 1H, CH═N); 7.06(s, 1H, CH); 5.93(d,



J=4.9Hz, 1H, CH); 5.32(d, J=4.9Hz, 1H, CH); 4.09(s, 3H, OCH3);



4.33 and 3.64(AB quartet, J=18.2Hz, 2H, SCH2).


21
(90 MHz, DMSO-d6): 3.65 and 4.7(AB quartet, J=18Hz, 2H, SCH2);



3.95(s, 3H, O—CH3); 4.2(part of the AB quartet, J=18Hz, 1H of



SCH2); 5.3(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz,



β-lactam-H); 7.0(s, 1H, thiazolyl-H); 7 to 7.7(m, 5H, aromatic H); 8.45



(s, 1H, CH═N);.9(d, J=8Hz, NH).


22
(90 MHz, DMSO-d6): 3.55 and 4.6(AB quartet, J=18Hz, 2H, SCH2);



3.93(s, 3H, O—CH3); 4.2(part of the AB quartet, J=18Hz, 1H of



SCH2); 5.3(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz,



β-lactam-H); 7.0(s, 1H, thiazolyl-H); 7 to 7.7(m, 5H, aromatic-H); 8.3



(s, 1H, CH═N); 9.9(d, J=8Hz, NH).


23
(90 MHz, DMSO-d6): 3.05(d, J=4Hz, 3H, NHCH3); 3.55 and 4.5



(AB quartet, J=18Hz, 2H, SCH2); 3.93(s, 3H, O—CH3); 4.2(part of the



AB quartet, J=18Hz, 1H of SCH2); 5.25(d, J=5Hz, 1H, β-lactam-



H); 5.8(dd, J=5Hz and 8Hz, β-lactam-H); 6.95(s, 1H, thiazolyl-H);



8.25(s, 1H, CH═N); 8.4(d, J=4Hz, NHCH3); 9.85(d, J=8Hz, NH).


24
(90 MHz, DMSO-d6): 2.85(s, 3H, NCH3); 3.1 to 3.7(m, 9H, 8 pipera-



zinyl-H's and 1H of SCH2); 3.95(s, 3 H, OCH3); 4.1(part of the AB



quartet, J=18Hz, 1H of SCH2); 3.95(s, 3H, O—CH3); 5.3(d, J=5Hz,



1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-lactam-H); 6.95(s, 1H,



thiazolyl-H); 7.95(s, 1H, CH═N); 9.9(d, J=8Hz, NH).


25
(90 MHz, DMSO-d6): 3.6 and 4.55(AB quartet, J=18Hz, 2H, SCH2);



3.9 to 4.1(m, 5H, —OCH3 and —N—CH2—CH═CH2); 5.1 to 5.5(m, 3H, β-



lactam-H and —N—CH2—CH═CH2); 5.7 to 6.1(m, 2H, β-lactam-H and N—



CH2—CH═CH2); 6.95(s, 1H, thiazolyl-H); 8.3(s, 1H, CH═N); 9.95(d, J=8Hz, NH).


26
(90 MHz, DMSO-d6): 1.7 to 2(m, 2H, —CH2—CH2—CH3); 3.1 to 3.5(m,



4H); 3.55 and 4.5(AB quartet, J=18Hz, 2H, SCH2); 3.95(s, 3H, O—



CH3); 5.3(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-



lactam-H); 6.95(s, 1H, thiazolyl-H); 8.3(s, 1H, CH═N); 9.9(d, J=8Hz, NH).


27
(90 MHz, DMSO-d6): 0.8 to 1.1 and 1.1 to 1.7(m, 7H, —CH2—CH2—CH3);



3.15 to 3.45(m, 2H, —NHCH2—); 3.6 and 4.55(AB quartet, J=18Hz,



2H, SCH2); 3.95(s, 3H, O—CH3); 5.3(d, J=5Hz, 1H, β-lactam-H);



5.85 (dd, J=5Hz and 8Hz, β-lactam-H); 6.95(s, 1H, thiazolyl-H); 8.4



(s, 1H, CH═N); 9.95(d, J=8Hz, NH).


28
(90 MHz, DMSO-d6): 3.05(d, J=4Hz, 3H, NHCH3); 3.65(s, 3H,



NCH3); 3.55 and 4.6(AB quartet, J=18Hz, 2H, SCH2); 3.93(s, 3H,



O—CH3); 4.2(part of the AB quartet, J=18Hz, 1H of SCH2); 5.3(d, J=



5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-lactam-H); 7.0(s,



1H, thiazolyl-H); 8.6(s, 1H, CH═N); 9.4(d, J=8Hz, NH).


29
300 MHz, DMSO-d6): 2.93(d, J=4.6Hz, 3H, NCH3); 3.4 to 3.6(m,



SH); 3.6 to 3.8(m, 4H); 3.93(s, 3H, O—CH3); 4.2(part of the AB



quartet, J=18Hz, 1H of SCH2); 5.3(d, J=5Hz, 1H, β-lactam-H); 5.85



(dd, J=5Hz and 8Hz, β-lactam-H); 6.93(s, 1H, thiazolyl-H); 8.6(s,



1H, CH═N); 9.92(d, J=8Hz, NH).


30
(90 MHz, DMSO-d6): 1.3(s, 9H, —C(CH3)3); 3.55 and 4.55(AB quartet,



J=18Hz, 2H, SCH2); 5.3(d, J=5Hz, 1H, β-lactam-H); 5.85(dd,



J=5Hz and 8Hz, β-lactam-H); 6.95(s, 1H, thiazolyl-H); 8.25(s, 1H,



CH═N); 9.95(d, J=8Hz, NH).


31
(90 MHz, DMSO-d6): 2.9(s, 3H, NCH3); 3.0(s, 6H, N(CH3)2); 3.6 and



4.2(AB quartet, J=18Hz, 2H, SCH2); 3.95(s, 3H, O—CH3); 5.3(d,



J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-lactam-H); 7.0(s,



1H, thiazolyl-H); 8.55(s, 1H, CH═N); 9.95(d, J=8Hz, NH).


32
(90 MHz, DMSO-d6) 2.85(s, 2H); 3.55 and 4.6(AB quartet, J=18Hz,



2H, SCH2); 3.95(s, 3H, O—CH3); 5.3(d, J=5Hz, 1H, β-lactam-H);



5.85 (dd, J=5Hz and 8Hz, β-lactam-H); 6.95(s, 1H, thiazolyl-H); 8.65



(s, 1H, CH═N); 9.9(d, J=8Hz, NH).


33
(90 MHz, DMSO-d6): 3.4 to 3.8(m, 9H, morpholino H's and 1H of



SCH2); 3.95(s, 3H, O—CH3); 4.6(part of the AB quartet, J=18Hz, 1H



of SCH2); 5.3(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and



8Hz, β-lactam-H); 6.95(s, 1H, thiazolyl-H); 8.7(s, 1H, CH═N); 9.9(d,



J=8Hz, NH).


34
(300 MHz, DMSO-d6): 3.32(s, 9H, —N+(CH3)3); 0.4 to 1(m, 4H,



—CH2—CH2—); 2.5 to 2.8(m, 1H); 3.65 and 4.17(AB quartet, J=18.1Hz, 2H,



SCH2); 3.94(s, 3H, O—CH3); 4.8(q, J=17Hz, 2H); 5.3(d, J=5Hz,



1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-lactam-H); 6.94(s, 1H,



thiazolyl-H); 8.26(s, 1H, CH═N); 9.93(d, J=8Hz, NH).


35
(90 MHz, DMSO-d6): 0.4 to 1(m, 4H, —CH2—CH2—); 2.5 to 2.8(m, 1H),



3.55 and 4.6(AB quartet, J=18Hz, 2H, SCH2); 3.95(s, 3H, O—CH3);



5.3 (d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz,



β-lactam-H); 6.9(s, 1H, thiazolyl-H); 8.35(s, 1H, CH═N); 9.85(d,



J=8Hz, NH).


36
(90 MHz, DMSO-d6): 3.6 and 4.55(AB quartet, J=18Hz, 2H, SCH2);



3.95 s, 3H, O—CH3); 5.3(d, J=5Hz, 1H, β-lactam-H); 5.85(dd,



J=5Hz and 8Hz, β-lactam-H); 6.9(s, 1H, thiazolyl-H); 8.5(s, 1H, CH═N);



9.85(d, J=8Hz, NH); 10.4(broad singulet, 1H, —NH—OH).


37
(90 MHz, DMSO-d6): 3.1(s, 3H, N—CH3); 3.55 and 4.6(AB quartet,



J=18Hz, 2H, SCH2); 3.9(s, 3H, O—CH3); 5.3(d, J=5Hz, 1H, β-lactam-



H); 5.85(dd, J=5Hz and 8Hz, β-lactam-H); 6.9(s, 1H, thiazolyl-H);



8.7(s, 1H, CH═N); 9.85(d, J=8Hz, NH).


38
(300 MHz, DMSO-d6): 3.56 and 4.54(AB quartet, J=18.1Hz, 2H,



SCH2); 3.91(s, 3H, O—CH3); 4.87(d, J=6.5Hz, 2H); 5.3(d, J=5Hz,



1H, β-lactam-H); 5.89(dd, J=5Hz and 8Hz, β-lactam-H); 6.88(s, 1H,



thiazolyl-H); 7.6(m, 2H, pyridinyl-H); 8.15(m, 1H, pyridinyl-H); 8.39



(s, 1H, CH═N); 8.86(m, 1H, pyridinyl-H); 9.83(d, J=8Hz, NH).


39
(300 MHz, DMSO-d6): 3.57 and 4.52(AB quartet, J=18.1Hz, 2H,



SCH2); 3.91(s, 3H, O—CH3); 4.87(d, J=6Hz, 2H); 5.3(d, J=5Hz,



1H, β-lactam-H); 5.89(dd, J=5Hz and 8Hz, β-lactam-H); 6.88(s, 1H,



thiazolyl-H); 8.15(m, 1H, pyridinyl-H); 8.38(s, 1H, CH═N); 8.45(m,



1H, pyridinyl-H); 8.8(m, 1H, pyridinyl-H); 8.85(s, 1H, pyridinyl-H);



9.91(d, J=8Hz, NH).


40
(300 MHz, DMSO-d6): 3.58 and 4.57(AB quartet, J=18.3Hz, 2H,



SCH2); 3.9(s, 3H, O—CH3); 5.06(broad singulet, 2H); 5.3(d, J=5Hz,



1H, β-lactam-H); 5.88(dd, J=5Hz and 8Hz, β-lactam-H); 6.94(s, 1H,



thiazolyl-H); 8.02(d, J=6.6Hz, 2H, pyridinyl-H); 8.4(s, 1H, CH═N);



8.92(d, J=6.6Hz, 2H, pyridinyl-H); 9.91(d, J=8Hz, NH).


41
(90 MHz, DMSO-d6): 3.65 and 4.35(AB quartet, J=18Hz, 2H, SCH2);



3.9(s, 3H, O—CH3); 4.2(d, J=7Hz, 2H); 5.2(d, J=5Hz, 1H, β-



lactam-H); 5.75(dd, J=5Hz and 8Hz, β-lactam-H); 6.95(s, 1H,



thiazolyl-H); 7.85(s, 1H, CH═N); 9.8(d, J=8Hz, NH).


42
(90 MHz, DMSO-d6): 2.95(broad duplet, 3H, N—CH3); 3.0 to 3.3(m,



4H, —CH2—N—CH2); 3.4 to 3.8(m, 5H, —CH2—NH+—CH2— and 1H of SCH2);



3.85(s, 3H, O—CH3); 4.1(part of the AB quartet, J=18Hz, 1H of



SCH2); 5.25(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz,



β-lactam-H); 6.8(s, 1H, thiazolyl-H); 8.65(s, 1H, CH═N); 9.75(d,



J=8Hz, NH).


43
(90 MHz, DMSO-d6): 3.7 and 4.85(AB quartet, J=18Hz, 2H, SCH2);



3.95(s, 3H, O—CH3); 5.35(d, J=5Hz, 1H, β-lactam-H); 5.95(dd,



J=5Hz and 8Hz, β-lactam-H); 7.0(s, 1H, thiazolyl-H); 7.2(t, J=6Hz,



1H, pyridinyl-H); 7.4(d, J=8Hz, 1H, pyridinyl-H); 8.15(t, J=6Hz,



2H, pyridinyl-H); 8.55(s, 1H, CH═N); 9.95(d, J=8Hz, NH).


44
(90 MHz, DMSO-d6): 3.6 and 4.05(AB quartet, J=18Hz, 2H, SCH2);



3.95(s, 3H, O—CH3); 5.25(d, J=5Hz, 1H, β-lactam-H); 5.75(dd,



J=5Hz and 8Hz, β-lactam-H); 6.9(s, 1H, thiazolyl-H); 8.5(s, 1H,



CH═N); 9.85(d, J=8Hz, NH).


45
(300 MHz, DMSO-d6): 1.4 to 1.7(m, 6H); 3.4 to 3.7(m, 5H, 



—CH2—N—CH2— and 1H of SCH2); 3.92(s, 3H, O—CH3); 4.55(part of the AB



quartet, J=18Hz, 1H of SCH2); 5.29(d, J=5Hz, 1H, β-lactam-H);



5.89(dd, J=5Hz and 7.8Hz, β-lactam-H); 6.89(s, 1H, thiazolyl-H);



8.6(s, 1H, CH═N); 9.84(d, J=7.8Hz, NH).


46
(90 MHz, DMSO-d6): 3.1 to 3.4(m, 4H, —CH2—NH+—CH2—); 3.65 and



4.65(AB quartet, J=18Hz, 2H, SCH2); 3.85(s, 3H, O—CH3); 4 to 4.3



(m, 4H, —CH2—N—CH2—); 4.65(part of the AB quartet, J=18Hz, 1H of



SCH2); 5.2(d, J=5Hz, 1H, β-lactam-H); 5.8(dd, J=5Hz and 8Hz,



β-lactam-H); 6.75(s, 1H, thiazolyl-H); 8.5(s, 1H, CH═N); 9.7(d,



J=8Hz, NH).


47
(300 MHz, DMSO-d6): 2.85(broad singulet, 3H, N—CH3); 3.54 and 4.52



(AB quartet, J=18.1Hz, 2H, SCH2); 3.93(s, 3H, O—CH3); 5.3(d,



J=5Hz, 1H, β-lactam-H); 5.89(dd, J=5Hz and 7.9Hz, β-lactam-H); 6.91



(s, 1H, thiazolyl-H); 8.62(s, 1H, CH═N); 9.88(d, J=7.9Hz, NH);



12.0(s, 1H, OH).


48
(90 MHz, DMSO-d6): 3.2(s, 6H, NCH3); 3.7(s, 4H, —N—(CH2)2—N—);



3.65 and 4.0(AB quartet, J=17.8Hz, 2H, SCH2); 3.95(s, 3H, O—CH3);



5.3(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz,



β-lactam-H); 6.95(s, 1H, thiazolyl-H); 8.8(s, 1H, CH═N); 9.9(d,



J=8Hz, NH).


49
(300 MHz, DMSO-d6): 3.7 and 4.13(AB quartet, J=17.8Hz, 2H,



SCH2); 3.9(s, 3H, O—CH3); 5.31(d, J=5Hz, 1H, β-lactam-H); 5.89



(dd, J=5Hz and 8Hz, β-lactam-H); 6.92(s, 1H, thiazolyl-H); 8.13(d,



J=6Hz, 2H, pyridinyl-H); 8.7(s, 1H, CH═N); 8.93(m, 3H, pyridinyl-



H); 9.88(d, J=8Hz, NH).


50
(300 MHz, DMSO-d6): 2.94(d, J=4.7Hz, 3H, N—CH3); 3.29(broad s,



6H, —N+(CH3)2); 3.3 to 3.7(m, 9H, piperazinyl-H's and 1H of SCH2); 3.93



(s, 3H, O—CH3); 4.2(part of the AB quartet, J=18Hz, 1H of SCH2);



5.28(d, J=5Hz, 1H, β-lactam-H); 5.89(dd, J=5Hz and 7.6Hz,



β-lactam-H); 6.9(s, 1H, thiazolyl-H); 8.1(s, 1H, formyl-H); 8.6(s, 1H,



CH═N); 9.9(d, J=8Hz, NH).


51
(300 MHz, DMSO-d6): 3.7 and 4.2(AB quartet, J=18Hz, 2H, SCH2);



3.93(s, 3H, O—CH3); 5.35(d, J=5Hz, 1H, β-lactam-H); 5.85(dd,



J=5Hz and 8Hz, β-lactam-H); 6.0(AB quartet, J=9Hz, 2H); 6.93(s,



1H, thiazolyl-H); 8.2(t, J=7Hz, 2H), 8.7(t, J=7Hz, 1H) and 9.1(d,



J=6Hz, 2H), pyridinium-H; 8.32(s, 1H, CH═N); 9.95(d, J=8Hz, NH).


52
(90 MHz, DMSO-d6): 3.7(s, 3H, N—CH3); 3.65 and 4.1(AB quartet,



J=18Hz, 2H, SCH2); 3.95(s, 3H, O—CH3); 5.35(d, J=5Hz, 1H,



β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-lactam-H); 7.0(s, 1H,



thiazolyl-H); 8.75(s, 1H, CH═N); 9.9(d, J=8Hz, NH).


53
(90 MHz, DMSO-d6): 2.25(s, 3H, triazinyl-CH3); 3.5 and 4.65(AB



quartet, J=18Hz, 2H, SCH2); 4.0(s, 3H, O—CH3); 5.35(d, J=5Hz,



1H, β-lactam-H); 5.85(dd, J=5Hz and 8 Hz, β-lactam-H); 6.95(s, 1H,



thiazolyl-H); 8.85(s, 1H, CH═N); 9.95(d, J=8Hz, NH).


54
(90 MHz, DMSO-d6): 2.3(s, 3H, CH3); 1.8 to 2.1(m, 1H); 3.6 and 4.55



(AB quartet, J=18Hz, 2H, SCH2); 3.95(s, 3H, O—CH3); 5.35(d,



J=5Hz, 1H, β-lactam-H); 5.9(dd, J=5Hz and 8Hz, β-lactam-H); 6.95(s,



1H, thiazolyl-H); 8.65(s, 1H, CH═N); 9.9(d, J=8Hz, NH).


55
(90 MHz, DMSO-d6): 2.8(broad duplet, 3H, N—CH3); 3.2 to 3.7(m, 5H,



N—CH2—CH2—O and 1H of SCH2); 3.95(s, 3H, O—CH3); 4.5(part of the



AB quartet, J=18Hz, 1H of SCH2); 5.3(d, J=5Hz, 1H, β-lactam-H);



5.85(dd, J=5Hz and 8Hz, β-lactam-H); 6.95(s, 1H, thiazolyl-H); 8.65



(s, 1H, CH═N); 9.9(d, J=8Hz, NH).


56
(90 MHz, DMSO-d6): 3.7 and 4.15(AB quartet, J=18Hz, 2H, SCH2);



4.0(s, 3H, O—CH3); 5.35(d, J=5Hz, 1H, β-lactam-H); 5.85(dd,



J=5Hz and 8Hz, β-lactam-H); 7.0(s, 1H, thiazolyl-H); 7 to 7.8(m, 4H,



aromatic-H); 8.45(s, 1H, CH═N); 9.95(d, J=8Hz, NH).


57
(90 MHz, DMSO-d6): 3.35 broad singulet, 3H, NCH3); 3.55 and 4.55



(AB quartet, J=18Hz, 2H, SCH2); 3.95(s, 3H, O—CH3); 5.3(d,



J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-lactam-H); 6.95(s,



1H, thiazolyl-H); 8.15(s, 1H, CH═N); 9.85(d, J=8Hz, NH).


58
(90 MHz, DMSO-d6): 2.95(broad duplet, 3H, NCH3); 3.35(broad



singulet, 3H, NCH3); 3.65 and 4.65(AB quartet, J=18Hz, 2H, SCH2);



3.95(s, 3H, O—CH3); 5.3(d, J=5Hz, 1H, β-lactam-H); 5.85(dd,



J=5Hz and 8Hz, β-lactam-H); 6.95(s, 1H, thiazolyl-H); 8.1(s, 1H,



CH═N); 9.85(d, J=8Hz, NH).


59
(90 MHz, DMSO-d6): 1 to 1.5(m, 4H, —CH2—CH2—); 1.8 to 2.1(m, 1H);



3.55 and 4.55(AB quartet, J=18Hz, 2H, SCH2); 3.95(s, 3H, O—CH3);



5.3(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz,



β-lactam-H); 6.9(s, 1H, thiazolyl-H); 8.65(s, 1H, CH═N); 9.9(d,



J=8Hz, NH).


60
(90 MHz, DMSO-d6): 3.7 and 4.8(AB quartet, J=18Hz, 2H, SCH2); 4.0



(s, 3H, O—CH3); 5.35(d, J=5Hz, 1H, β-lactam-H); 5.95(dd, J=5Hz



and 8Hz, β-lactam-H); 7.0(s, 1H, thiazolyl-H); 7.85(dd, J=4Hz and



6Hz, pyridinyl-H); 8.2(dt, J=2 and 8Hz, pyridinyl-H); 8.5(d,



J=6Hz, pyridinyl-H); 8.9(d, J=4Hz, pyridinyl-H); 8.95(s, 1H, CH═N);



9.95(d, J=8Hz, NH).


61
(90 MHz, DMSO-d6): 3.6 and 4.15(AB quartet, J=18Hz, 2H, SCH2);



3.85(s, 3H, O—CH3); 5.25(d, J=5Hz, 1H, β-lactam-H); 5.85(dd,



J=5Hz and 8Hz, β-lactam-H); 6.75(s, 1H, thiazolyl-H); 7.5(dd,



J=5Hz and 8Hz, pyridinyl-H); 8.25(broad duplet, J=8Hz, pyridinyl-H);



8.65(broad triplet, J=6Hz, pyridinyl-H); 9.05(s, 1H, CH═N); 9.7(d,



J=8Hz, NH).


62
(300 MHz, DMSO-d6): 3.13(broad duplet, 3H, N—CH3); 3.29(broad s,



6H, N+(CH3)2); 3.4 to 3.75(m, 5H, —CH2—N+—CH2— and 1H of SCH2); 3.85



(s, 3H, O—CH3); 4 to 4.3(m, 4H, —CH2—N—CH2—); 4.65(part of the AB



quartet, J=18Hz, 1H of SCH2); 5.27(d, J=5Hz, 1H, β-lactam-H);



5.85(dd, J=5Hz and 7.6Hz, β-lactam-H); 6.78(s, 1H, thiazolyl-H);



8.75(s, 1H, CH═N); 9.75(d, J=7.6Hz, NH).


63
(90 MHz, DMSO-d6 +TFA): 3.0(broad duplet, 3H, N—CH3); 3.2(s, 9H,



N+(CH3)3); 3.5 to 3.8(m, 5H, N—CH2—CH2—N+ and 1H of SCH2); 3.90(s,



3H, O—CH3); 4.65(part of the AB quartet, J=18Hz, 1H of SCH2); 5.3



(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-lactam-



H); 6.8(s, 1H, thiazolyl-H); 8.75(s, 1H, CH═N); 9.75(d, J=8Hz,



NH).


64
(90 MHz, DMSO-d6): 3.65 and 4.15(AB quartet, J=18Hz, 2H, SCH2);



4.0(s, 3H, O—CH3); 5.25(d, J=5Hz, 1H, β-lactam-H); 5.8(dd,



J=5Hz and 8Hz, β-lactam-H); 7.0(s, 1H, thiazolyl-H); 7.2(d, J=5Hz,



1H, pyrimidinyl-H); 8.45(s, 1H, CH═N); 8.8(d, J=5Hz, 1H,



pyrimidinyl-H); 9.9(d, J=8Hz, NH).


65
(90 MHz, DMSO-d6 +TFA): 4.0(s, 3H, O—CH3); 3.6 and 4.65(AB



quartet, J=18Hz, 2H, SCH2); 5.25(d, J=5Hz, 1H, β-lactam-H); 5.85



(dd, J=5Hz and 8Hz, β-lactam-H); 7.0(s, 1H, thiazolyl-H); 8.3(s,



1H, CH═N); 9.85(d, J=8Hz, NH).


66
(90 MHz, DMSO-d6): 3.2(broad singulet, 3H, N—CH3); 3.0 to 3.4(m,



4H, —CH2—N—CH2); 3.4 to 3.8(m, 5H, —CH2—NH+—CH2—and 1H of SCH2);



3.95(s, 3H, O—CH3); 4.3(part of the AB quartet, J=18Hz, 1H of



SCH2); 5.35(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz,



β-lactam-H); 7.0(s, 1H, thiazolyl-H); 8.15(s, 1H, CH═N); 9.9(d,



J=8Hz, NH).


67
(90 MHz, DMSO-d6): 3.3(s, 3H, N—CH3); 3.3(broad s, 6H, N+(CH3)2);



3.3 to 3.7(m, 9H, piperazinyl-H's and 1H of SCH2); 3.85(s, 3H,



O—CH3); 4.25(part of the AB quartet, J=18Hz, 1H of SCH2); 5.25(d,



J=5Hz, 1H, β-lactam-H); 5.8(dd, J=5Hz and 8Hz, β-lactam-H); 6.8(s,



1H, thiazolyl-H); 8.1(s, 1H, formyl-H); 8.15(s, 1H, CH═N); 9.75(d,



J=8Hz, NH).


68
(90 MHz, DMSO-d6): 2.25(s, 3H); 3.65(s, 3H, N—CH3); 3.7 and 4.6



(AB quartet, J=18Hz, 2H, SCH2); 3.9(s, 3H, O—CH3); 5.3(d,



J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-lactam-H); 6.05(d,



J=4Hz, pyrrol-H); 6.85(d, J=4Hz, pyrrol-H); 6.9(s, 1H, thiazolyl-



H); 8.75(s, 1H, CH═N); 9.9(d, J=8Hz, NH).


69
(90 MHz, DMSO-d6): 3.5 and 4.45(AB quartet, J=20Hz, 2H, SCH2);



5.25(d, J=5Hz, 1H, β-lactam-H); 5.75(d, J=55Hz, 2H, —CH2F); 5.85



(dd, J=5Hz and 8Hz, β-lactam-H); 8.25(s, 1H, CH═N); 9.85(d,



J=8Hz, NH).


70
(300 MHz, DMSO-d6): 1.13(t, J=7.1Hz, 3H, CH3); 3.31(qd, J=7.1 and



ca. 6Hz, 2H, CH2); 3.55 and 4.47(AB quartet, J=18.1Hz, 2H, S—CH2);



5.29(d, J=5.0Hz, 1H, β-lactam-H); 5.89(dd, J=5.0 and 7.9Hz, 1H,



β-lactam-H); 6.78(s, 1H, CH thiazol); 8.01(broad, 2H, NH); 8.19(broad



t 1H, NH) ; 8.32(s, 1H, CH═N); 9.70(d, J=7.9Hz, 1H, NH); 12.03(s,



1H, OH).


71
(300 MHz, DMSO-d6): 2.98(d, J=4.6Hz, 3H, N—CH3); 3.56 and 4.46



(AB quartet, J=18.1Hz, 2H, S—CH2); 5.28(d, J=4.9Hz, 1H, β-lactam-H);



5.87(dd, J=4.9 and 7.9Hz, 1H, β-lactam-H); 6.83(s, 1H, CH thiazol);



8.22(s, 1H, CH═N); 8.48(q broad J=4.6Hz, 1H, NH); 9.75(d, J=7.9Hz,



1H, NH); 11.63(s, 1H, OH); 12.28(s, 1H, OH).


72
(300 MHz, DMSO-d6): 3.53 and 4.47(AB quartet, J=18.1Hz, 2H,



S—CH2); 5.26(d, J=5.0Hz, 1H, β-lactam-H); 5.88(dd, J=4.9 and 7.9Hz,



1H, β-lactam-H); 6.84(s, 1H, CH thiazol); 8.00(s, 1H, NH); 8.23(s, 1H,



CH═N); 8.28(s, 1H, NH); 9.76(d, J=7.9Hz, 1H, NH); 11.56(s, 1H,



OH); 12.31(s, 1H, OH).


73
(300 MHz, DMSO-d6): 1.16(t, J=7.1Hz, 3H, CH3); 1.90(m broad, 4H,



CH2); 3.39(qd, J=7.1 and ca. 6Hz, 2H, CH2); 3.56(m broad, 4H, CH2);



3.63 and 4.07(AB quartet, J=18.0Hz, 2H, S—CH2); 5.28(d, J=5.0Hz,



1H, β-lactam-H); 5.88(dd, J=5.0 and 7.8Hz, 1H, β-lactam-H); 6.81(s,



1H, CH thiazol); 7.97(t broad, J=ca. 6Hz 1H, NH); 8.60(s, 1H,



CH═N); 9.76(d, J=7.8Hz, 1H, NH); 11.70(s, 1H, OH); 12.26(s, 1H,



OH).


74
(300 MHz, DMSO-d6): 3.57 and 4.48(AB quartet, J=18.1Hz, 2H,



S—CH2); 3.97(broad, 2H, N—CH2—C═C); 5.1-5.3(m, 2H, C═CH2); 5.30(d,



J=5.1Hz, 1H, β-lactam-H); 5.8-5.9(m, 1H, C—CH═C); 5.89(dd, J=4.9



and 8.2Hz, 1H, β-lactam-H); 6.83(s, 1H, CH thiazol); 8.10(s, 2H, NH);



8.34(s, 1H, CH═N); 8.41(s, 1H, NH); 9.77(d, J=8.0Hz, 1H, NH); 12.26



(s, 1H, OH); 12.38(s, 1H, OH).


75
(300 MHz, DMSO-d6): 1.89(m broad 2H, CH2); 3.33(s broad, 4H,



N—CH2); 3.54 and 4.42(AB quartet, J=18.1Hz, 2H, S—CH2); 5.29(d,



J=5.0Hz, 1H, β-lactam-H); 5.89(dd, J=5.0 and 8.0Hz, 1H, β-lactam-H);



6.76(s, 1H, CH thiazol); 8.29(s, 1H, CH═N); 8.38(s, 2H, NH); 9.66(d,



J=8.0Hz, 1H, NH); 11.90(s, 1H, OH); 12.03(s, 1H, OH).


76
(300 MHz, DMSO-d6): 0.89(t, 3H, C—CH3); 1.2-1.4(m, 2H, C—CH2—C);



1.4-1.6(m, 2H, C—CH2—C); 3.2-3.4(m, 2H, N—CH2—C); 3.56 and 4.47(AB



quartet, J=18.1Hz, 2H, S—CH2); 5.30(d, J=5.0Hz, 1H, β-lactam-H); 5.89



(dd, J=5.0 and 7.9Hz, 1H, β-lactam-H); 6.83(s, 1H, CH thiazol); 8.04(s,



2H, NH); 8.24(s, 1H, CH═N); 8.32(s, 1H, NH); 9.76(d, J=7.9Hz, 1H,



NH); 12.13(s, 1H, OH); 12.36(s, 1H, OH).


77
(300 MHz, DMSO-d6): 3.66 and 3.92(AB quartet, J=17.9Hz, 2H,



S—CH2); 3.86(s, 3H, O—CH3); 5.27(d, J=5.0Hz, 1H, β-lactam-H); 5.88



(dd, J=5.0 and 7.8Hz, 1H, β-lactam-H); 6.84(s, 1H, CH thiazol); 8.22(s,



1H, CH═N); 9.78(d, J=7.8Hz, 1H, NH); 12.34(s, 1H, OH).


78
(300 MHz, DMSO-d6): 1.39(s, 9H, C—CH3); 3.56 and 4.47(AB quartet,



J=18.0Hz, 2H, S—CH2); 5.29(d, J=5.0Hz, 1H, β-lactam-H); 5.89(dd,



J=5.0 and 7.9Hz, 1H, β-lactam-H); 6.81(s, 1H, CH thiazol); 7.90(s



broad 2H, NH); 7.99(s broad 1H, NH); 8.25(s, 1H, CH═N); 9.68(d,



J=7.9Hz, 1H, NH); 12.03(s, 1H, OH); 12.16(s, 1H, OH).


79
(300 MHz, DMSO-d6): 2.92(d, J=4.8Hz, 3H, N—CH3); 3.03(s, 6H,



N—CH3); 3.61 and 4.17(AB quartet, J=18.0Hz, 2H, S—CH2); 5.29(d,



J=5.0Hz, 1H, β-lactam-H); 5.88(dd, J=5.0 and 7.8Hz, 1H, β-lactam-H);



6.81(s, 1H, CH thiazol); 8.20(q broad J=4.8Hz, 1H, NH); 8.55(s, 1H,



CH═N); 9.76(d, J=7.5Hz, 1H, NH); 11.83(s, 1H, OH); 12.28(s, 1H,



OH).


80
(300 MHz, DMSO-d6): 2.75(s, 2H, N—CH2); 3.55 and 4.54(AB quartet,



J=18.1Hz, 2H, S—CH2); 5.32(d, J=5.1Hz, 1H, β-lactam-H); 5.93(dd,



J=5.1 and 7.9Hz, 1H, β-lactam-H); 6.79(s, 1H, CH thiazol); 8.59(s, 1H,



CH═N); 9.73(d, J=8.0Hz, 1H, NH); 12.13(s, 1H, OH).


81
(300 MHz, DMSO-d6): 3.55 and 4.54(AB quartet, J=18.1Hz, 2H,



S—CH2); 3.5-3.6(m, 4H, CH2); 3.6-3.7(m, 4H, CH2); 5.30(d, J=5.1Hz,



1H, β-lactam-H); 5.89(dd, J=5.0 and 7.9Hz, 1H, β-lactam-H); 6.84(s,



1H, CH thiazol); 8.35(broad, 2H, NH); 8.65(s, 1H, CH═N); 9.80(d,



J=7.9Hz, 1H, NH); 12.27(s, 1H, OH); 12.51(s, 1H, OH).


82
(300 MHz, DMSO-d6): 0.64(m, 2H, cyclopr. CH2); 0.83(m, 2H, cyclopr.



CH2); 2.62(m, 1H, cyclopr. CH); 3.53 and 4.49(AB quartet, J=18.1Hz,



2H, S—CH2); 5.29(d, J=5.0Hz, 1H, β-lactam-H); 5.89(dd, J=5.0 and



8.0Hz, 1H, β-lactam-H); 6.79(s, 1H, CH thiazol); 8.09(s, 2H, NH); 8.35



(s, 1H, CH═N); 8.59(s, 1H, NH); 9.70(d, J=8.0Hz, 1H, NH); 12.08(s,



1H, OH); 12.13(s, 1H, OH).


83
(300 MHz, DMSO-d6): 3.54 and 4.48(AB quartet, J=18.1Hz, 2H,



S—CH2); 5.29(d, J=5.0Hz, 1H, β-lactam-H); 5.89(dd, J=4.9 and 7.8Hz,



1H, β-lactam-H); 6.83(s, 1H, CH thiazol); 8.15(s, 2H, NH); 8.39(s, 1H,



CH═N); 9.79(d, J=7.9Hz, 1H, NH); 11.21(s, 1H, OH); 12.15(s, 1H,



OH); 12.44(s, 1H, OH).


84
(300 MHz, DMSO-d6): 3.09(s, 6H, N—CH3); 3.55 and 4.55(AB quartet,



J=18.1Hz, 2H, S—CH2); 5.30(d, J=5.0Hz, 1H, β-lactam-H); 5.89(dd,



J=5.0 and 7.8Hz, 1H, β-lactam-H); 6.84(s, 1H, CH thiazol); 8.07(s, 2H,



NH); 8.65(s, 1H, CH═N); 9.81(d, J=7.9Hz, 1H, NH); 11.86(s, 1H,



OH); 12.53(s, 1H, OH).


85
(300 MHz, DMSO-d6): 3.58 and 4.50(AB quartet, J=18.0Hz, 2H,



S—CH2); 4.90(d, J=6.4Hz, 2H, N—CH2); 5.31(d, J=5.1Hz, 1H,



β-lactam-H); 5.90(dd, J=5.2 and 7.8Hz, 1H, β-lactam-H); 6.84(s, 1H,



CH thiazol); 7.6-7.8(m, 2H, CH aromatic); 8.1-8.3(m, 1H, CH



aromatic); 8.35(s broad, 1H, NH); 8.39(s, 1H, CH═N); 8.7-8.8(m, 2H,



CH aromatic); 9.3(broad, 1H, NH); 9.78(d, J=7.8Hz, 1H, NH); 12.42



(s, 1H, OH); 12.49(s, 1H, OH).


86
(300 MHz, DMSO-d6): 3.57 and 4.52(AB quartet, J=18.0Hz, 2H,



S—CH2); 4.85(d, J=6.6Hz, 2H, N—CH2); 5.30(d, J=5.0Hz, 1H,



β-lactam-H); 5.90(dd, J=5.0 and 7.8Hz, 1H, β-lactam-H); 6.82(s, 1H,



CH thiazol); 7.9-8.1(m, 1H, CH aromatic); 8.38(s, 1H, CH═N); 8.4-8.6



(m, 1H, CH aromatic); 8.8-8.9(m, 1H, CH aromatic); 8.9-9.0(m, 1H, CH



aromatic); 8.7-8.8(m, 2H, CH aromatic); 9.77(d, J=7.9Hz, 1H, NH);



12.32(s, 1H, OH); 12.45(s, 1H, OH).


87
(300 MHz, DMSO-d6): 3.57 and 4.52(AB quartet, J=18.1Hz, 2H,



S—CH2); 4.98(d, J=6.2Hz, 2H, N—CH2); 5.30(d, J=5.0Hz, 1H,



β-lactam-H); 5.90(dd, J=5.0 and 7.9Hz, 1H, β-lactam-H); 6.81(s, 1H,



CH thiazol); 7.9-8.0(m, 2H, CH aromatic); 8.40(s, 1H, CH═N); 8.8-9.0



(m, 1H, CH aromatic); 9.00(s broad 1H, NH); 9.76(d, J=7.9Hz, 1H,



NH); 12.30(s, 1H, OH); 12.56(s, 1H, OH).


88
(300 MHz, DMSO-d6): 3.68 and 4.05(AB quartet, J=17.9Hz, 2H,



S—CH2); 4.19 and 4.38(AB quartet, J=16.4Hz, 2H, N—CH2—C═O); 5.30(d,



J=5.0Hz, 1H, β-lactam-H); 5.87(dd, J=5.0 and 7.7Hz, 1H, β-lactam-H);



6.87(s, 1H, CH thiazol); 7.86(s, 1H, CH═N); 9.82(d, J=7.7Hz, 1H,



NH); 11.35(s, 1H, OH); 12.45(s, 1H, OH).


89
(300 MHz, DMSO-d6): 3.58 and 4.64(AB quartet, J=18.1Hz, 2H,



S—CH2); 5.29(d, J=4.9Hz, 1H, β-lactam-H); 5.89(dd, J=4.9 and 7.9Hz,



1H, β-lactam-H); 6.84(s, 1H, CH thiazol); 7.1-7.6(m, CH aromatic);



8.33(s, 1H, CH═N); 9.78(d, J=7.9Hz, 1H, NH); 10.03(s, 1H, NH);



11.86(s, 1H, OH); 12.35(s, 1H, OH).


90
(300 MHz, DMSO-d6): 3.66 and 4.70(AB quartet, J=18.1Hz, 2H,



S—CH2); 5.34(d, J=5.0Hz, 1H, β-lactam-H); 5.92(dd, J=5.0 and 7.9Hz,



1H, β-lactam-H); 6.84(s, 1H, CH thiazol); 7.0-7.2(m, 1H, CH aromatic);



7.2-7.3(m, 1H, CH aromatic); 8.0-8.2(m, 2H, CH aromatic); 8.49(s, 1H,



CH═N); 9.79(d, J=8.0Hz, 1H, NH); 12.32(s, 1H, OH); 13.41(s, 1H,



OH).


91
(300 MHz, DMSO-d6): 3.65 and 4.03(AB quartet, J=17.8Hz, 2H,



S—CH2); 5.27(d, J=4.9Hz, 1H, β-lactam-H); 5.83(dd, J=4.9 and 7.7Hz,



1H, β-lactam-H); 6.88(s, 1H, CH thiazol); 8.52(s, 1H, CH═N); 9.77(d,



J=7.7Hz, 1H, NH); 11.08(s, 1H, OH); 12.35(s, 1H, OH).


92
(300 MHz, DMSO-d6): 1.51(s, 3H, C—CH3); 1.54(s, 3H, C—CH3); 2.86(d,



J=4.9Hz, 3H, N—CH3); 3.55 and 4.50(AB quartet, J=18.2Hz, 2H,



S—CH2); 5.32(d, J=5.1Hz, 1H, β-lactam-H); 5.96(dd, J=5.0 and 8.2Hz,



1H, β-lactam-H); 6.95(s, 1H, CH thiazol); 8.03(s broad 2H, NH); 8.18



(s broad 1H, NH); 8.32(s, 1H, CH═N); 9.74(d, J=7.9Hz, 1H, NH);



12.19(s, 1H, OH).


93
(300 MHz, DMSO-d6): 2.9(broad, 3H, N—CH3); 3.54 and 4.50(AB



quartet, J=18.1Hz, 2H, S—CH2); 5.30(d, J=5.1Hz, 1H, β-lactam-H); 5.89



(dd, J=5.0 and 7.8Hz, 1H, β-lactam-H); 6.83(s, 1H, CH thiazol); 8.62(s,



1H, CH═N); 9.79(d, J=7.9Hz, 1H, NH); 11.98(s, 1H, OH); 12.42(s,



1H, OH).


94
(300 MHz, DMSO-d6): 3.39(m broad 2H, CH2); 3.54(m broad 2H, CH2);



2.89(d, J=4.6Hz, 3H, N—CH3); 3.55 and 4.49(AB quartet, J=18.0Hz,



2H, S—CH2); 5.30(d, J=5.0Hz, 1H, β-lactam-H); 5.90(dd, J=5.0 and



7.9Hz, 1H, β-lactam-H); 6.79(s, 1H, CH thiazol); 8.61(s, 1H, CH═N);



9.71(d, J=7.9Hz, 1H, NH); 11.73(s, 1H, OH); 12.10(s, 1H, OH).


95
(300 MHz, DMSO-d6): 2.26(s, 3H, CH3); 3.57 and 4.70(AB quartet,



J=18.0Hz, 2H, S—CH2); 5.33(d, J=5.0Hz, 1H, β-lactam-H); 5.93(dd,



J=5.0 and 7.9Hz, 1H, β-lactam-H); 6.83(s, 1H, CH thiazol); 8.77(s, 1H,



CH═N); 9.80(d, J=7.9Hz, 1H, NH); 12.40(s, 1H, OH).


96
(300 MHz, DMSO-d6): 3.22(m broad 4H, N—CH2); 3.55 and 4.52(AB



quartet, J=18.1Hz, 2H, S—CH2); 3.85(m broad 4H, N—CH2); 5.30(d,



J=5.0Hz, 1H, β-lactam-H); 5.90(dd, J=5.0 and 7.9Hz, 1H, β-lactam-H);



6.82(s, 1H, CH thiazol); 8.5(broad, 2H, NH); 8.65(s, 1H, CH═N); 9.76



(d, J=7.9Hz, 1H, NH); 9.82(s, 2H, NH); 12.31(s, 1H, OH); 12.47(s,



1H, OH).


97
(300 MHz, DMSO-d6): 3.14(s, 6H, N—CH3); 3.64 and 3.94(AB quartet,



J=17.9Hz, 2H, S—CH2); 3.68(s 4H, N—CH2); 5.28(d, J=5.0Hz, 1H,



β-lactam-H); 5.89(dd, J=5.0 and 7.7Hz, 1H, β-lactam-H); 6.81(s, 1H,



CH thiazol); 8.64(s, 1H, CH═N); 9.77(d, J=7.7Hz, 1H, NH); 12.29(s,



1H, OH); 12.36(s, 1H, OH).


98
(300 MHz, DMSO-d6): 3.33(s, 3H, N—CH3); 3.54 and 4.55(AB quartet,



J=18.3Hz, 2H, S—CH2); 5.29(d, J=5.0Hz, 1H, β-lactam-H); 5.91(dd,



J=5.1 and 7.9Hz, 1H, β-lactam-H); 6.76(s, 1H, CH thiazol); 8.10(s, 1H,



CH═N); 8.2(s, NH); 9.67(d, J=7.8Hz, 1H, NH); 11.92(s, 1H, OH).


99
(300 MHz, DMSO-d6): 2.80(s, 3H, CH3); 3.57 and 4.48(AB quartet,



J=18.1Hz, 2H, S—CH2); 5.34(d, J=5.1Hz, 1H, β-lactam-H); 5.94(dd,



J=5.1 and 7.9Hz, 1H, β-lactam-H); 6.82(s, 1H, CH thiazol); 8.55(s, 1H,



CH═N); 9.28(s, 1H, NH); 9.80(d, J=7.9Hz, 1H, NH); 9.90(s, 1H, NH);



12.39(s, 1H, OH); 13.52(s, 1H, OH).


100
(300 MHz, DMSO-d6): 3.58 and 4.46(AB quartet, J=18.1Hz, 2H,



S—CH2); 5.34(d, J=5.1Hz, 1H, β-lactam-H); 5.94(dd, J=5.1 and 7.9Hz,



1H, β-lactam-H); 6.82(s, 1H, CH thiazol); 8.28(dd, J=6.7 and 14.8Hz,



1H, N—CH═N); 8.58(s, 1H, CH═N); 9.58(d, J=14.8Hz 1H, NH); 9.77



(d, J=8.0Hz, 1H, NH); 9.9(d, J=6.7Hz 1H, NH); 12.29(s, 1H, OH).


101
(300 MHz, DMSO-d6): 3.57 and 4.48(AB quartet, J=18.0Hz, 2H,



S—CH2); 3.9(s, 3H, O—CH3); 5.33(d, J=5.1Hz, 1H, β-lactam-H); 5.92



(dd, J=5.1 and 8.0Hz, 1H, β-lactam-H); 6.87(s, 1H, CH thiazol); 8.27



(dd, J=6.9 and 14.6Hz, 1H, N—CH═N); 8.60(s, 1H, CH═N); 9.55(d,



J=14.4Hz 1H, NH); 9.79(d, J=8.0Hz, 1H, NH); 9.91(d, J=6.5Hz 1H,



NH).


102
(300 MHz, DMSO-d6): 1.49(s, 3H, C—CH3); 1.50(s, 3H, C—CH3); 3.54



and 4.48(AB quartet, J=18.1Hz, 2H, S—CH2); 5.31(d, J=4.9Hz, 1H,



β-lactam-H); 5.97(dd, J=4.9 and 8Hz, 1H, β-lactam-H); 6.84(s, 1H, CH



thiazol); 8.29(s, 1H, CH═N); 9.65(d, J=8Hz, 1H, NH); 12.06(s, 1H,



OH).


103
(300 MHz, DMSO-d6): 1.51(s, 3H, C—CH3); 1.53(s, 3H, C—CH3); 3.52



and 4.52(AB quartet, J=18.3Hz, 2H, S—CH2); 5.30(d, J=5.0Hz, 1H,



β-lactam-H); 5.95(dd, J=5.0 and 8.1Hz, 1H, β-lactam-H); 6.94(s, 1H,



CH thiazol); 7.61(s broad 2H, NH); 8.15(s broad 2H, NH); 8.38(s, 1H,



CH═N); 9.74(d, J=8.1Hz, 1H, NH); 11.20(s, 1H, OH); 12.16(s, 1H,



OH).


104
(300 MHz, DMSO-d6): 1.49(s, 3H, C—CH3); 1.51(s, 3H, C—CH3); 3.56



and 4.52(AB quartet, J=1 8.3Hz, 2H, S—CH2); 4.90(d, J=6.3Hz, 2H,



CH2); 5.32(d, J=5.0Hz, 1H, β-lactam-H); 5.97(dd, J=5.0 and 8.1Hz,



1H, β-lactam-H); 6.91(s, 1H, CH thiazol); 7.6-7.8(m 2H, CH aromatic);



8.2-8.3(m 1H, CH aromatic); 8.38(s, 1H, CH═N); 8.6-8.8(m 1H, CH



aromatic); 9.71(d, J=8.2Hz, 1H, NH); 12.48(s, 1H, OH).


105
(300 MHz, DMSO-d6): 0.64(m broad 2H, CH2); 0.84(m broad 2H, CH2);



1.50(s, 3H, C—CH3); 1.52(s, 3H, C—CH3); 2.61(m broad 1H, N—CH);



3.53 and 4.53(AB quartet, J=18.2Hz, 2H, S—CH2); 5.31(d, J=5.0Hz,



1H, β-lactam-H); 5.96(dd, J=5.0 and 8.2Hz, 1H, β-lactam-H); 6.90(s,



1H, CH thiazol); 8.10(s broad 2H, NH); 8.34(s, 1H, CH═N); 8.60(s



broad 1H, NH); 9.70(d, J=8.2Hz, 1H, NH); 12.08(s, 1H, OH).


106
(300 MHz, DMSO-d6): 1.50(s, 3H, C—CH3); 1.52(s, 3H, C—CH3); 2.87



(broad 6H, N—CH3); 3.54 and 4.51(AB quartet, J=18.1Hz, 2H, S—CH2);



5.33(d, J=5.0Hz, 1H, β-lactam-H); 5.96(dd, J=5.0 and 8.1Hz, 1H,



β-lactam-H); 6.91(s, 1H, CH thiazol); 8.06(s broad 1H, NH); 8.30(s



broad 1H, NH); 8.62(s, 1H, CH═N); 9.71(d, J=8.4Hz, 1H, NH); 11.76



(s, 1H, OH).


107
(300 MHz, DMSO-d6): 1.51(s, 3H, C—CH3); 1.53(s, 3H, C—CH3); 1.8-2.0



(m, 4H, C—CH2); 1.8-2.0(m, 4H, N—CH2); 3.54 and 4.55(AB quartet,



J=18.1Hz, 2H, S—CH2); 5.31(d, J=5.0Hz, 1H, β-lactam-H); 5.95(dd,



J=5.0 and 8.3Hz, 1H, β-lactam-H); 6.90(s, 1H, CH thiazol); 7.70(s



broad NH); 7.93(s broad NH); 8.63(s, 1H, CH═N); 9.62(d, J=8.2Hz,



1H, NH); 9.75(s, 1H, NH); 11.71(s, 1H, OH).


108
(300 MHz, CD3OD): 8.59(s, 1H, CH═N); 6.94(s, 1H, CH); 5.95(d,



J=5.0Hz, 1H, CH); 5.29(d, J=5.0Hz, 1H, CH); 4.02(s, 3H, OCH3);



4.34 and 3.61(AB quartet, J=18.0Hz, 2H, SCH2); 2.73(s, 3H, SCH3).


109
(300 MHz, DMSO-d6): 0.64(m broad 2H, CH2 cyclopr); 0.84(m broad



2H, CH2 cyclopr); 2.62(m broad 1H, N—CH cyclopr); 3.54 and 4.51(AB



quartet, J=18.1Hz, 2H, S—CH2); 4.66(s, 2H, O—CH2); 5.30(d, J=5.0Hz,



1H, β-lactam-H); 5.93(dd, J=5.0 and 8.1Hz, 1H, β-lactam-H); 6.93(s,



1H, CH thiazol); 8.09(broad 2H, NH); 8.35(s, 1H, CH═N); 8.58(broad,



1H, NH); 9.77(d, J=8.0Hz, 1H, NH); 12.04(s, 1H, OH).


110
(300 MHz, DMSO-d6): 2.87(s, 6H, N—CH3); 3.56 and 4.50(AB quartet.



J=18.0Hz, 2H, S—CH2); 4.67(s, 2H, O—CH2); 5.32(d, J=5.0Hz, 1H,



β-lactam-H); 5.92(dd, J=5.0 and 8.1Hz, 1H, β-lactam-H); 6.94(s, 1H,



CH thiazol); 8.1(broad 1H, NH); 8.35(broad 1H, NH); 8.63(s, 1H,



CH═N); 9.80(d, J=8.1Hz, 1H, NH); 11.77(s, 1H, OH).


111
(300 MHz, DMSO-d6): 1.93(broad, 4H, C—CH2); 3.47(broad, 4H,



N—CH2); 3.55 and 4.54(AB quartet, J=17.9Hz, 2H, S—CH2); 4.67(s, 2H,



O—CH2); 5.30(d, J=5.0Hz, 1H, β-lactam-H); 5.92(dd, J=5.0 and 7.9Hz,



1H, β-lactam-H); 6.94(s, 1H, CH thiazol); 7.96(broad 2H, NH); 8.62(s,



1H, CH═N); 9.79(d, J=7.8Hz, 1H, NH); 11.72(s, 1H, OH).


112
(300 MHz, DMSO-d6): 3.62 and 4.67(AB quartet, J=18.1Hz, 2H,



S—CH2); 5.37(d, J=5.1Hz, 1H, β-lactam-H); 5.96(dd, J=5.1 and 7.9Hz,



1H, β-lactam-H); 6.83(s, 1H, CH thiazol); 7.7-7.9(m, 1H, CH aromatic);



8.1-8.3(m, 1H, CH aromatic); 8.4-8.6(m, 1H, CH aromatic); 8.8-8.9(m,



1H, CH aromatic); 8.97(s, 1H, CH═N); 9.79(d, J=7.9Hz, 1H, NH); 9.85



(s, 1H, NH); 10.37(s, 1H, NH); 12.31(s, 1H, OH).


113
(300 MHz, DMSO-d6): 1.1-1.3(m, 2H, CH2 cyclopr); 1.2-1.4(m, 2H,



CH2 cyclopr); 1.9-2.0(m, 1H, CH2 cyclopr); 3.54 and 4.49(AB quartet,



J=18.1Hz, 2H, S—CH2); 5.32(d, J=5.1Hz, 1H, β-lactam-H); 5.93(dd,



J=5.1 and 8.0Hz, 1H, β-lactam-H); 6.76(s, 1H, CH thiazol); 8.59(s, 1H,



CH═N); 9.07(s, 1H, NH); 9.23(s, 1H, NH); 9.67(d, J=8.0Hz, 1H, NH);



11.92(s, 1H, OH); 13.27(s, 1H, OH).


114
(300 MHz, DMSO-d6): 1.59(broad, 6H, C—CH2); 3.53(broad 4H, N—CH2);



3.6 and 4.52(AB quartet, J=18.4Hz, 2H, S—CH2); 5.29(d, J=5.0Hz, 1H,



β-lactam-H); 5.89(dd, J=5.0 and 7.6Hz, 1H, β-lactam-H); 6.82(s, 1H,



CH thiazol); 8.16(s 2H, NH); 8.60(s, 1H, CH═N); 9.75(d, J=7.6Hz,



1H, NH); 11.94(s, 1H, OH); 12.30(s, 1H, OH).


115
(300 MHz, DMSO-d6): 3.5 and 4.53(AB quartet, J=17.9Hz, 2H, S—CH2);



3.4-3.7(m, 8H, N—CH2); 5.31(d, J=5.0Hz, 1H, β-lactam-H); 5.90(dd,



J=5.0 and 7.9Hz, 1H, β-lactam-H); 6.82(s, 1H, CH thiazol); 8.08(s, 1H,



CH═O); 8.38(broad 2H, NH); 8.62(s, 1H, CH═N); 9.75(d, J=7.9Hz,



1H, NH); 12.18(s, 1H, OH); 12.28(s, 1H, OH).


116
(300 MHz, DMSO-d6/D2O): 2.81(s, 6H, N—CH3); 2.92(s, 3H, C═N—CH3);



3.54 and 4.58(AB quartet, J=18.1Hz, 2H, S—CH2); 3.6(broad, 2H,



N—CH2); 3.97(broad, 2H, N—CH2); 5.30(d, J=4.8Hz, 1H, β-lactam-H);



5.90(d, J=4.8Hz, 1H, β-lactam-H); 6.81(s, 1H, CH thiazol); 8.55(s, 1H,



CH═N).


117
(300 MHz, DMSO-d6/D20): 2.91(s, 3H, C═N—CH3); 3.19(s, 9H, N—CH3);



3.29(broad, 2H, N—CH2); 3.56 and 4.48(AB quartet, J=18.1Hz, 2H,



S—CH2); 3.82(broad, 2H, N—CH2); 5.31(d, J=5.0Hz, 1H, β-lactam-H);



5.90(d, J=5.0Hz, 1H, β-lactam-H); 6.84(s, 1H, CH thiazol); 8.56(s, 1H,



CH═N).


118
(300 MHz, DMSO-d6): 3.61 and 4.59(AB quartet, J=18.0Hz, 2H,



S—CH2); 5.35(d, J=5.1Hz, 1H, β-lactam-H); 5.59(dd, J=5.1 and 7.9Hz,



1H, β-lactam-H); 6.82(s, 1H, CH thiazol); 6.9-7.1(m, 1H, CH aromatic);



7.2-7.4(m, 2H, CH aromatic); 8.74(s, 1H, CH═N); 9.31(s 1H, NH/OH);



9.76(s 1H, NH/OH); 9.78(d, J=7.9Hz, 1H, NH); 12.25(s, 1H, OH);



13.03(s, 1H, OH).


119
(300 MHz, DMSO-d6): 2.30(s, 3H, C—CH3); 3.59 and 4.57(AB quartet,



J=18.1Hz, 2H, S—CH2); 3.67(s, 3H, N—CH3); 5.34(d, J=5.1Hz, 1H,



β-lactam-H); 5.94(dd, J=5.1 and 8.0Hz, 1H, β-lactam-H); 6.13(d,



J=3.9Hz 1H, CH Pyrrol); 6.77(s, 1H, CH thiazol); 6.86(d, J=3.9Hz 1H,



CH Pyrrol); 8.66(s, 1H, CH═N); 9.25(s 1H, NH); 9.46(s 1H, NH); 9.70



(d, J=8.0Hz, 1H, NH); 11.96(s, 1H, OH); 12.90(s, 1H, OH).


120
(300 MHz, DMSO-d6): 3.71 and 4.12(AB quartet, J=17.9Hz, 2H,



S—CH2); 5.32(d, J=5.1Hz, 1H, β-lactam-H); 5.91(dd, J=5.0 and 7.9Hz,



1H, β-lactam-H); 6.84(s, 1H, CH thiazol); 7.9-8.0(m, 2H, CH aromatic);



8.66(s, 1H, CH═N); 8.8-8.9(m, 2H, CH aromatic); 8.8(broad 1H, NH);



9.76(d, J=8.0Hz, 1H, NH); 12.17(s, 1H, OH); 12.37(s, 1H, OH).


121
(300 MHz, DMSO-d6): 3.22(s, 6H, N—CH3); 3.54 and 4.55(AB quartet,



J=18.5Hz, 2H, S—CH2); 3.6(broad, 4H, N—CH2); 4.0(broad, 4H, N—CH2);



5.30(d, J=5.0Hz, 1H, β-lactam-H); 5.91(dd, J=5.0 and 7.9Hz, 1H,



β-lactam-H); 6.82(s, 1H, CH thiazol); 8.73(s, 1H, CH═N); 9.75(d,



J=7.6Hz, 1H, NH); 12.30(s, 1H, OH); 12.76(s, 1H, OH).


122
(300 MHz, DMSO-d6): 2.76(s, 3H, N—CH3); 3.1-3.3(broad, 2H, N—CH2);



3.4-3.6(broad, 2H, N—CH2); 3.5-3.7(broad, 2H, N—CH2); 3.55 and 4.53



(AB quartet, J=18.1Hz, 2H, S—CH2); 4.2-4.4(broad, 2H, N—CH2); 5.31(d,



J=5.0Hz, 1H, β-lactam-H); 5.90(dd, J=5.0 and 7.8Hz, 1H, β-lactam-H);



6.82(s, 1H, CH thiazol); 8.66(s, 1H, CH═N); 9.77(d, J=7.8Hz, 1H,



NH); 11.74(s, 1H, NH); 12.36(s, 1H, OH); 12.56(s, 1H, OH).


123
(300 MHz, DMSO-d6): 2.90(d, J=4.7Hz 3H, N—CH3); 3.34(s, 3H,



N—CH3); 3.55 and 4.59(AB quartet, J=18.1Hz, 2H, S—CH2); 5.30(d,



J=5.0Hz, 1H, β-lactam-H); 5.91(dd, J=5.0 and 7.9Hz, 1H, β-lactam-H);



6.81(s, 1H, CH thiazol); 8.09(s, 1H, CH═N); 8.25(s, 2H, NH); 8.37(s,



1H, NH); 9.72(d, J=7.9Hz, 1H, NH); 12.14(s, 1H, OH).


124
(300 MHz, DMSO-d6): 2.81(d, J=4.3Hz 6H, N—CH3); 3.2-3.4(in broad



2H, N—CH2); 3.56 and 4.55(AB quartet, J=18.0Hz, 2H, S—CH2); 3.7-3.9



(m broad 2H, N—CH2); 5.30(d, J=4.9Hz, 1H, β-lactam-H); 5.9(dd, J=4.9



and 7.9Hz, 1H, β-lactam-H); 6.82(s, 1H, CH thiazol); 8.3(broad, NH);



8.38(s, 1H, CH═N); 8.47(broad, NH); 9.76(d, J=7.9Hz, 1H, NH);



10.84(s, 1H, NH); 12.31(s, 2H, OH).


125
(300 MHz, DMSO-d6): 2.82(d, J=4.5Hz 6H, N—CH3); 3.2-3.3(m broad



2H, N—CH2); 3.40(s, 3H, N—CH3); 3.56 and 4.73(AB quartet, J=18.3Hz,



2H, S—CH2); 3.8-3.9(m broad 2H, N—CH2); 5.29(d, J=5.0Hz, 1H,



β-lactam-H); 5.91(dd, J=5.0 and 7.8Hz, 1H, β-lactam-H); 6.82(s, 1H,



CH thiazol); 8.11(s, 1H, CH═N); 8.68(s, 2H, NH); 8.74(m broad 1H,



NH); 9.77(d, J=7.9Hz, 1H, NH); 10.91(s, 1H, OH); 12.32(s, 1H, OH).


126
(300 MHz, DMSO-d6): 3.60 and 4.56(AB quartet, J=18.1Hz, 2H,



S—CH2); 5.32(d, J=5.0Hz, 1H, β-lactam-H); 5.92(dd, J=5.0 and 7.9Hz,



1H, β-lactam-H); 6.83(s, 1H, CH thiazol); 6.8-6.9(m, 1H, CH aromatic);



7.1-7.2(m, 1H, CH aromatic); 7.3-7.4(m, 1H, CH aromatic); 8.23(s, 1H,



CH═N); 8.37(2H, NH/OH); 8.51(s, 1H, CH═N); 9.78(d, J=7.9Hz, 1H,



NH); 12.27(s, 1H, OH).


127
(300 MHz, DMSO-d6): 3.53 and 4.49(AB quartet, J=18.1Hz, 2H,



S—CH2); 5.29(d, J=5.0Hz, 1H, β-lactam-H); 5.89(dd, J=5.0 and 7.9Hz,



1H, β-lactam-H); 6.79(s, 1H, CH thiazol); 7.93(broad, 2H, NH); 8.37



(broad, 1H, CH═N); 9.73(d, J=7.8Hz, 1H, NH); 12.15(s, 1H, OH).


128
(300 MHz, DMSO-d6): 3.25(broad, 4H, N—CH2); 3.31(s, 3H, N—CH2);



3.62 and 4.27(AB quartet, J=18.0Hz, 2H, S—CH2); 3.74(broad, 4H,



N—CH2); 5.30(d, J=5.0Hz, 1H, β-lactam-H); 5.89(dd, J=4.9 and 7.9Hz,



1H, β-lactam-H); 6.79(s, 1H, CH thiazol); 8.11(s, 1H, CH═N); 9.03



(broad, 1H, NH); 9.31(broad, 1H, NH); 9.67(d, J=7.9Hz, 1H, NH); 9.87



(s, 2H, NH); 12.07(s, 1H, OH).


129
(300 MHz, DMSO-d6): 0.70(m; 4H, —CH2—CH2—); 3.05(m, 1H); 3.51 and



4.49(AB quartet, J=18Hz, 2H, SCH2); 4.38(s, 3H, O—CH3); 5.24(d,



J=4.9Hz, 1H, β-lactam-H); 5.84(dd, J=7.9Hz and 4.9Hz, 1H, β-lactam-



H); 6.86(s, 1H, thiazolyl-H); 8.19(d, J=3.9Hz, 1H); 8.21(s, 1H, CH═N);



9.72(d, J=8.0Hz, 1H, NH); 11.58(s, 1H).


130
(300 MHz, CD3CN + D20): 1.26(t, J=7Hz, 3H); 1.68(sextet, J=7Hz,



2H); 1.93(quintet, J=7Hz, 2H); 3.93(t, J=7.1Hz, 2H); 3.95(s, 3H,



O—CH3); 3.98 and 4.57(AB quartet, J=18Hz, 2H, SCH2); 5.59(d, J=4.9Hz,



1H, β-lactam-H); 6.18(d, J=4.9Hz, 1H, β-lactam-H); 7.40(s, 1H,



thiazolyl-H); 8.63(s, 1H, CH═N).


131
(300 MHz, D20): 0.74(m, 2H); 0.88(m, 2H); 2.58 and 2.38(two



singulets, 3H, SCH3); 2.68(m, 1H); 3.45 and 3.94(AB-system, broad, 2H,



SCH2); 3.95(s, 3H, O—CH3); 5.23(d, J=4.7Hz, 1H, β-lactam-H); 5.75(d,



J=4.7Hz, 1H, β-lactam-H); 7.03(s, 1H, thiazolyl-H); 8.36(s, broad, 1H,



CH═N).


132
(300 MHz, D2O): 0.82(t, J=7.3Hz, 3H); 1.29(sextet, J=7Hz, 2H); 1.56



(quintet, J=7Hz, 2H); 2.61 and 2.46(two singulets, 3H, SCH3); 3.46(t,



J=7.1Hz, 2H); 3.55 and 4.01(AB quartet, J=18Hz, 2H, SCH2); 3.98(s,



3H, O—CH3); 5.25(d, J=4.9Hz, 1H, β-lactam-H); 5.78(d, J=4.9Hz, 1H,



β-lactam-H); 7.05(s, 1H, thiazolyl-H); 8.39(s, 1H, CH═N).


133
(300 MHz, DMSO-d6): 2.68(m, 2H); 3.73(m, 2H); 3.57 and 4.23(AB



quartet, J=18Hz, 2H, SCH2); 3.96(s, 3H, O—CH3); 5.29(d, J=4.9Hz, 1H,



β-lactam-H); 8.48(dd, J=8Hz and J=4.9Hz, 1H, β-lactam-H); 6.91(s,



1H, thiazolyl-H); 8.24(s, 1H, CH═N); 9.20(s, 1H); 9.90(d, J=8.0Hz,



1H NH).


134
(300 MHz, DMSO-d64 D20): 0.68(m, 2H); 0.84(m, 2H); 2.91(m, 1H);



3.62 and 4.22(AB quartet, J=18Hz, 2H, SCH2); 5.28(d, J=4.9Hz, 1H,



β-lactam-H); 5.85(d, J=4.8Hz, 1H, β-lactam-H); 7.06(s, 1H, thiazolyl-



H); 8.23(s, 1H, CH═N).


135
(300 MHz, DMSO-d6): 0.89(t, J=7 Hz, 3H); 1.29(sextet, J=7Hz, 2H);



1.54(quintet, J=7Hz, 2H); 3.51 and 4.47(AB quartet, J=18Hz, 2H,



SCH2); 3.52(m, 2H); 5.24(d, J=4.8Hz, 1H, β-lactam-H); 5.85(dd,



J=7.9Hz and 4.8Hz, 1H, β-lactam-H); 6.69(s, 1H, thiazolyl-H); 8.21(s,



1H, CH═N); 8.47(m, 1H); 9.55(d, J=7.9Hz, 1H, NH); 11.44(s, 1H);



11.54(s, 1H).


136
(300 MHz, DMSO-d6): 2.77(s, 3H, NCH3); 3.0-3.2(m, 4H); 3.35-3.6(m,



4H); 3.63 and 4.03(AB quartet, J=18Hz, 2H, SCH2); 3.95(s, 3H,



OCH3); 5.26(d, J=4.9Hz, 1H, β-lactam-H); 5.84(dd, J=7.9Hz and J=4.9



Hz, 1H, β-lactam-H); 6.85(s, 1H, thiazolyl-H); 8.40(s, 1H, CH═N); 9.69



(d, J=8.0Hz, 1H, NH); 11.67(s, 1H).


137
(300 MHz, DMSO-d6): 3.59 and 4.54(AB quartet, J=18.2Hz, 2H,



SCH2); 3.66(d, J=4Hz, 3H, NHCH3); 3.95(s, 3H, O—CH3); 5.26(d,



J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz, β-lactam-H);



6.95(s, 1H, thiazolyl-H); 7.96(s, 1H, CH═N); 8.4(d, J=4Hz,



NHCH3); 9.84(d, J=8Hz, NH).


138
(300 MHz, DMSO-d6): 1.43(s, 9H, —OC(CH3)3); 3.62 and 4.02(AB



quartet, J=17.8Hz, 2H, SCH2); 5.25(d, J=4.9Hz, 1H, β-lactam-H);



5.83(dd, J=4.9 and 8.0Hz, 1H, β-lactam-H); 6.93(s, 1H, thiazolyl-H);



8.20(s, 1H, CH═N); 9.69(d, J=8.0Hz, 1H, NH).


139
(300 MHz, DMSO-d6): 3.21(broad singulet, 4H); 3.89(broad singulet,



4H); 3.50 and 4.53(AB quartet, J=18.1Hz, 2H, SCH2); 5.27(d,



J=5Hz, 1H, β-lactam-H); 5.77(d, J=58Hz, 2H, —CH2F); 5.90(dd, J=5Hz



and 8.2Hz, β-lactam-H); 8.66(s, 1H, CH═N); 9.85(d, J=8.2Hz, NH).


140
(300 MHz, DMSO-d6): 1.02(t, J=7.4Hz, 3H, C—CH3); 2.32(qd, J=7.4



and 7.5Hz, 2H, C═C—CH2—C); 3.52 and 4.15(AB, J=17.7Hz, 2H,



S—CH2); 5.17(d, J=5.2Hz, 1H, β-lactam-H); 5.73(dd, J=5.2 and 8.8Hz,



1H, β-lactam-H); 6.48(s, 1H, CH thiazol); 6.61(t, J=7.5Hz, 1H,



C═CH—C); 8.93(s, 1H, CH═N); 9.14(d, J=8.8Hz, 1H, NH).


141
(90 MHz, DMSO-d6): 2.3(s, 3H, CH3); 1.8 to 2.1(m, 1H); 3.95(s, 2H,



SCH2); 3.9(s, 3H, O—CH3); 5.35(d, J=5Hz, 1H, β-lactam-H); 5.9(dd,



J=5Hz and 8Hz, β-lactam-H); 6.95(s, 1H, thiazolyl-H); 8.65(s, 1H,



CH═N); 9.9(d, J=8Hz, NH).


142
(90 MHz, DMSO-d6): 2.3(s, 3H, thiazolyl-CH3); 4.0(s, 3H, O—CH3);



3.75 and 4.3(AB quartet, J=18Hz, 2H, SCH2); 5.4(d, J=5Hz, 1H,



β-lactam-H); 5.95(dd, J=5Hz and 8Hz, β-lactam-H); 6.7(s, 1H,



thiazolyl-H); 7.05(s, 1H, thiazolyl-H); 8.55(s, 1H, CH═N); 9.95(d,



J=8Hz, NH).


143
(90 MHz, DMSO-d6): 2.25(s, 3H, thiazolyl-CH3); 3.60(s, 3H, N—CH3);



3.7 and 4.15(AB quartet, J=18Hz, 2H, SCH2); 3.95(s, 3H, O—CH3);



5.35(d, J=5Hz, 1H, β-lactam-H); 5.85(dd, J=5Hz and 8Hz,



β-lactam-H); 6.7(s, 1H, thiazolyl-H); 7.02(s, 1H, thiazolyl-H); 8.15(s,



1H, CH═N); 9.95(d, J=8Hz, NH).


144
(300 MHz, DMSO-d6): 2.83(d, 3H, NCH3); 3.55 and 4.23(AB quartet,



J=19.8Hz, 2H, SCH2); 3.84(s, 3H, ═N—OCH3); 5.21(d, J=5.5Hz, 1H,



β-lactam-H); 5.70(dd, J=5.5Hz and 9Hz, β-lactam-H); 6.77(s, 1H,



thiazolyl-H); 9.28(s, 1H, CH═N); 9.63(d, J=9Hz, 1H, NH).


145
(300 MHz, DMSO-d6):



Diastereomer A: 1.25(d, J=6Hz, 3H); 1.24(d, J=6Hz, 3H); 1.53(d,



J=5.4Hz, 3H, —O(CH3)CH—O—); 2.9(d, J=4.9Hz, 3H, NCH3); 3.62



and 4.61(AB quartet, J=18.3Hz, 2H, SCH2); 3.94(s, 3H, ═N—OCH3);



4.75 to 4.84(m, 1H, —O—CH(CH3)2); 5.34(d, J=5Hz, 1H, β-lactam-H);



5.94(dd, J=5Hz and 7.8Hz, β-lactam-H); 6.9(q, J=5.3Hz, 1H,



—O(CH3)CH—O—); 6.92(s, 1H, thiazolyl-H); 8.3(s, 1H, CH═N); 9.96(d,



J=7.8Hz, 1H, NH).



Diastereomer B: 1.24(d, J=6Hz, 3H); 1.22(d, J=6Hz, 3H); 1.51(d,



J=5.5Hz, 3H, —O(CH3)CH—O—); 2.9(d, J=4.9Hz, 3H, NCH3); 3.60 and



4.65(AB quartet, J=18.3Hz, 2H, SCH2); 3.93(s, 3H, ═N—OCH3); 4.75



to 4.84(m, 1H, —O—CH(CH3)2); 5.30(d, J=5Hz, 1H, β-lactam-H); 6.04



(dd, J=5Hz and 7.6Hz, β-lactam-H); 6.8(q, J=5.3, 1H, —O(CH3)CH—O—);



6.92(s, 1H, thiazolyl-H); 8.14(s, 1H, CH═N); 9.95(d, J=7.6Hz,



1H, NH).


146
(300 MHz, DMSO-d6):



Diastereomer A: 1.25(d, J=6Hz, 6H); 1.50(d, J=5.4Hz, 3H,



O(CH3)CH—O—); 2.18(s, 3H, CH3CO); 3.76 and 4.48(AB quartet,



J=17.9Hz, 2H, SCH2); 4.7 to 4.9(m, 1H, —O—CH(CH3)2); 5.31(d,



J=4.8Hz, 1H, β-lactam-H); 5.88(dd, J=4.8Hz and 7.6Hz, β-lactam-H);



6.87(q, J=5.3Hz, 1H, —O(CH3)CH—O—); 7.1(s, 1H, thiazolyl-H); 8.28



(s, 1H, CH═N); 9.93(d, J=7.6Hz, 1H, NH).



Diastereomer B: 1.23(d, J=6Hz, 6H); 1.49(d, J=5.4Hz, 3H,



—O(CH3)CH—O—); 2.17(s, 3H, CH3CO); 3.70 and 4.38(AB quartet,



J=18Hz, 2H, SCH2); 4.7 to 4.9(m, 1H —O—CH(CH3)2); 5.28(d, J=4.8Hz,



1H, β-lactam-H); 5.83(dd, J=4.8Hz and 7.6Hz, β-lactam-H); 6.80(q,



J=5.2, 1H, —O(CH3)CH—0—); 7.1(s, 1H, thiazolyl-H); 8.18(s, 1H,



CH═O); 9.91(d, J=7.6Hz, 1H, NH).


147
(300 MHz, DMSO-d6)



Diastereomer A: 1.26(d, J=6.2Hz, 6H); 1.53(d, J=5Hz, 3H,



—O(CH3)CH—O—); 2.29(s, 6H, 2 aryl-CH3); 3.60 and 4.54(AB quartet,



J=18.5Hz, 2H, SCH2); 4.75 to 4.84(m, 1H, —O—CH(CH3)2); 5.34(d,



J=5Hz, 1H, β-lactam-H); 5.97(dd, J=5Hz and 7.7Hz, β-lactam-H); 6.91



(q, J=5.3Hz, 1H, —O(CH3)CH—O—); 6.92(s, 1H, thiazolyl-H); 7.12 and



7.49(AB quartet, J=8Hz, 2 × 4 aromatic-H); 8.34(s, 1H, CH═N); 9.69



(d, J=7.7Hz, 1H, NH).



Diastereomer B: 1.24(d, J=6.2Hz, 6H); 1.52(d, J=5.5Hz, 3H,



O(CH3)CH—O—); 2.29(3.6H, 2 Aryl-CH3); 3.59 and 4.51(AB quartet,



J=18.4Hz, 2H, SCH2); 4.75 to 4.84(m, 1H, —O—CH(CH3)2); 5.31(d,



J=5Hz, 1H, β-lactam-H); 5.93(dd, J=5Hz and 7.7Hz, β-lactam-H); 6.83



(q, J=5.3, 1H, —O(CH3)CH—O—); 6.84(s, 1H, thiazolyl-H); 7.12 and 7.49



(AB quartet, J=8Hz, 2 × 4 aromatic-H); 8.24(s, 1H, CH═N); 9.69(d,



J=7.7Hz, 1H, NH).


A) a)
(D2O + DCl): 3.62(AB quartet, J=16Hz, 2H, S—CH2); 5.10(2d, J=5Hz,



2H, β-lactam-H); 6.20(s, broad, 1H, O—CH—O).


A) c)
(DMSO-d6): 3.55 and 3.73(AB quartet, J=18Hz) resp. 3.70(s), (2H,



S—CH2); 3.87(s, 3H, N—O—CH3), 5.11(d, J=5Hz, β-lactam-H); 5.87(m,



1H, β-lactam-H); 6.20 resp. 6.26(s, 1H, O—CH—O); 6.77 resp. 6.78(s, 1H,



thiazolyl-H); 7.27-7.35(m, 15H, Ar—H); 9.6(s, broad, 1H, NH-thiazolyl);



9.72 resp. 9.74(d, J=8Hz, 1H, NH).


A) d)
(DMSO-d6): 3.58 and 3.76(AB quartet, J=18Hz) resp. 3.72(s), (2H,



S—CH2); 3.88(s, 3H, N—O—CH3), 5.15(d, J=5Hz, β-lactam-H); 5.94(dd,



J=8Hz and 5Hz, 1H, β-lactam-H); 6.21 resp. 6.28(s, 1H, O—CH—O); 6.81



resp. 6.82(s, 1H, thiazolyl-H); 9.77 resp. 9.78(d, J=8Hz, 1H, NH).


B) c)
(CDCl3): 3.2-3.5(m, 2H, S—CH2); 5.05(d, J=5Hz, β-lactam-H); 6.0(dd,



J=5 and 8Hz, 1H, β-lactam-H); 6.4(s, 1H, O—CH—O); 7-7.4(m, 30H,



Ar—H).


B) d)
(DMSO-d6): 3.72(m, 2H, S—CH2); 5.15(d, J=5Hz, β-lactam-H); 5.95



(dd, J=8Hz and 5Hz, 1H, β-lactam-H); 6.3(broad s, 1H, O—CH—O); 6.8(s,



1H, thiazolyl-H); 9.75(d, J=8Hz, 1H, NH).


C)
(300 MHz, DMSO-d6): 3.55 and 3.77(AB quartet, J=18Hz) resp. 3.71(s),



(2H, S—CH2); 5.14(d, J=5Hz, β-lactam-H); 5.97(m, 1H, β-lactam-H); 5.79



(d, J=55Hz, 2H, —CH2F); 6.20 resp. 6.27(s, 1H, O—CH—O); 9.81 resp. 9.84



(d, J=8Hz, 1H, NH).


D)
(300 MHz, DMSO-d6): 2.20 resp. 2.21(s, 3H, O—C—CH3); 3.63 and 3.80(AB



quartet, J=18Hz) resp. 3.76(s) (2H, S—CH2); 5.20(d, J=5Hz, 1H, β-lactam-



H); 6.00(dd, J=8Hz and 5Hz, 1H, β-lactam-H); 6.23 resp. 6.29(s, 1H,



O—CH—O); 7.16 resp. 7.17(s, 1H, CH thiazol); 10.04 resp. 10.05(d, J=8Hz, 1H,



NH).


E)
(300 MHz, DMSO-d6): 3.58 and 3.79(AB quartet, J=18.2Hz) resp. 3.75(s)



(2H, S—CH2); 5.17(d, J=5Hz, 1H, β-lactam-H); 5.94(dd, J=8Hz and 5Hz,



1H, β-lactam-H); 6.21 resp. 6.28(s, 1H, O—CH—O); 6.85 resp. 6.86(s, 1H,



CH thiazol); 9.74(d, J=8Hz, 1H, NH); 12.38(s, 1H, OH).


F) c)
(300 MHz, DMSO-d6): 1.4(2s, 6H, C—(CH3)2); 1.5(s, 9H, C-(CH3)3); 3.6 and



3.7(AB quartet, J=18Hz) resp. 3.7(s)(2H, S—CH2); 5.2(d, J=5Hz, 1H,



β-lactam-H); 5.9(dd, J=8Hz and 5Hz, 1H, β-lactam-H); 6.2 resp. 6.3(s, 1H,



O—CH—O); 6.8(s, 1H, CH thiazol); 7.2-7.5(m, 15H, CH aromatic); 9.6(d,



J=8Hz, 1H, NH).


F) d)
(300 MHz, DMSO-d6): 1.48 resp. 1.50(s, 6H, C—(CH3)2); 3.60 and 3.77(AB



quartet, J=18Hz) resp. 3.74(s)(2H, S—CH2); 5.19(d, J=5.2Hz, 1H,



β-lactam-H); 6.01(dd, J=8.5Hz and 5.2Hz, 1H, β-lactam-H); 6.23 resp. 6.29(s,



1H, O—CH—O); 6.87 resp. 6.88(s, 1H, CH thiazol); 9.67(d, J=8.5Hz, 1H,



NH).


G)
(300 MHz, DMSO-d6): 1.00(t, J=7.5Hz, 3H, C—CH3); 1.47(s, 9H,



O—C(—CH3)3); 2.27(qd, J=7.5Hz, 2H, C═C—CH2—C); 3.57 and 3.74(AB



quartet, J=18.3Hz) resp. 3.73(s)(2H, S—CH2); 5.11(d, J=5.1Hz, 1H,



β-lactam-H); 5.88(dd, J=8.5Hz and 5.1Hz, 1H, β-lactam-H); 6.22 resp.



6.26(s, 1H, O—CH—O); 6.56(t, J=7.5Hz, 1H, C═CH—C); 7.05(s, 1H, CH



thiazol); 8.80 resp. 8.81(d, J=8.4Hz, 1H, NH).


H) a)
(300 MHz, DMSO-d6): 2.7(s, 3H, S—CH3); 3.5-3.6(m, 4H, N—CH2); 3.7-



3.8(m, 2H, N—CH2); 3.8-3.9(m, 2H, N—CH2); 8.1(s, 1H, CH═O); 9.6



(broad, 2H, NH).


H) b)
(300 MHz, DMSO-d6): 3.42(s, 4H, N—CH2); 3.4-3.6(m, 4H, N—CH2); 4.8



(broad, 2H, NH); 7.9(broad, 2H, NH); 8.1(s, 1H, CH═O); 9.5(broad,



1H, NH).


H) c)
(300 MHz, DMSO-d6): 3.1-3.2(s, 4H, N—CH2); 3.7-3.8(m, 4H, N—CH2);



4.8(broad, 2H, NH); 8.0(broad, 2H, NH); 9.6(broad, 1H, NH); 10.0



(broad, 2H, NH).


I)
(90 MHz, D2O): 1.2 ppm(t, 3H); 1.9-2.1 ppm(m, 4H); 3.3-3.7 ppm



(m, 6H).


J)
(90 MHz, DMSO-d6): 2.9 ppm(d, J=5Hz, 3H, NCH3), 3.4-3.8 ppm



(m, 8H), 7.55 ppm(broad quartet, 1H, NH).


K)
(90 MHz, D2O): 1.3 ppm(s, 9H).


L)
(90 MHz, DMSO-d6 + D2O): 2.8 ppm(s, 3H, NCH3); 3.4-3.65 ppm



(m, 4H); 4.0-4.4 ppm(m, 4H).


M)
(300 MHz, DMSO-d6): 2.74(s, 3H, C═N—CH3); 3.15(s, 9H, N(CH3)3);



3.49(m broad, 2H, N—CH2); 3.64(m broad, 2H, N—CH2); 4.8(broad, 2H,



NH); 7.8(broad, 3H, NH).


N)
(90 MHz, DMSO-d6): 2.85 ppm(s, 3H, NCH3); 3.2-3.65 ppm(m, 8H);



8.1 ppm(s, 1H, CH═O).


O)
(90 MHz, DMSO-d6 + D2O): 2.85 ppm(s, 3H, NCH3); 3.2-3.5 ppm



(m, 4H); 3.5-3.9 ppm(m, 4H).


P)
(300 MHz, D2O): 2.84(s, 3H, N—CH3); 3.3-3.4(m, 2H, N—CH2); 3.7-3.8



(m, 2H, N—CH2).


Q) a)
(90 MHz, DMSO-d6): 2.65 ppm(s, 3H, S—CH3); 3.35 ppm(s, 6H,



NCH3)2); 3.65-4.0 ppm(m, 4H); 4.0-4.3 ppm(m, 4H), 9.45 ppm



(broad singulet, 1H, NH).


Q) b)
(90 MHz, DMSO-d6): 3.3 ppm(s, 6H, NCH3)2); 3.5-3.8 ppm(m, 4H);



3.8-4.2 ppm(m, 4H).


R) a)
(90 MHz, DMSO-d6): 2.55 ppm(s, 3H, SCH3); 3.45 ppm(s, 3H,



NCH3).


R) b)
(90 MHz, DMSO-d6): 3.15 ppm(s, 3H, NCH3); 3.2-3.28 ppm(m, 2H);



3.28-3.35 ppm(m, 2H); 3.4-3.55 ppm(m, 4H); 5.18 ppm(broad



singulet, 2H); 8.05(s, 1H, —CH═0); 8.1-8.3(broad singulet, 2H).


R) c)
(300 MHz, DMSO-d6): 3.16 ppm(m, 3 + 4H); 3.63 ppm(m, 4H); 6.7



ppm(broad singulet, 5H); 8.5(broad singulet, 1H); 10.0 ppm(broad



singulet, 2H).


S)
(300 MHz, DMSO d6): 2.55(s, 2H, N—CH2); 5.92(s, 2H, NH).


T)
(300 MHz, DMSO d6): 0.5(m, 2H, CH2); 0.7-0.8(m, 2H, CH); 2.4-2.5



(m, 1H, N—CH); 4.7(broad, 2H, NH); 7.5(broad, 2H, NH); 8.2(broad,



1H, NH); 8.9(broad, 1H, NH).


U)
(300 MHz, DMSO d6): 2.7(s, 3H, N—CH3); 4.7(broad, 2H, NH); 7.7



(broad, 1H, NH); 9.2(broad, 1H, NH/OH); 9.8(broad, 1H, NH/OH).


V)
(300 MHz, DMSO d6): 2.79(d, J=4.8Hz 6H, N(CH3)2); 3.20(s, 3H,



N—CH3); 3.2(m, 2H, N—CH2); 3.6(m, 2H, N—CH2); 4.7(very broad, 2H,



NH); 7.7(broad, 2H, NH); 10.4(broad, 1H, NH).


W)
(300 MHz, D2O): 6.75-6.85(m, 1H, CH aromatic); 6.9-7.0(m, 1H, CH



aromatic); 7.1-7.15(m, 1H, CH aromatic); 7.7(s, 1H, CH═N).


X)
(300 MHz, D2O): 2.0(m, 1H); 2.47, 2.35(s, s, together 3H, —SCH3); 0.84



(m, 2H); 0.69(m, 2H).


Y)
(300 MHz, D2O): 3.36(t, J=7Hz, 2H); 2.51, 2.43(s, s, together 3H,



—SCH3); 1.55(quintet, J=7Hz, 2H); 1.29(sextet, J=7Hz, 2H); 0.85(t,



J=7Hz, 3H).


Z)
(90 MHz, DMSO-d6): 3.65 ppm(s, 3H, NCH3).


AA) a)
(300 MHz, DMSO d6): 2.19(s, 3H, C—CH3); 3.84(s, 3H, N—CH3); 5.84(d,



J=3.8Hz 1H, C═CH); 6.58(d, J=3.8Hz 1Hz, C═CH); 8.76(s, 1H, NH);



8.93(s, 1H, NH).


AA) b)
(300 MHz, DMSO d6): 2.3(s, 3H, C—CH3); 2.75(s, 3H, S—CH3); 3.65(s,



3H, N—CH3); 6.2(d, J=4Hz 1H, C═CH); 7.1(d, J=4Hz 1Hz, C═CH); 10.6



(s, broad 5H, NH).


AA) c)
(300 MHz, DMSO d6): 2.2(s, 3H, C—CH3); 3.1(s, 3H, N—CH3); 5.95(d,



J=4Hz 1H, C═CH); 6.5(d, J=4Hz 1Hz, C═CH); 7.2(very broad 5H, NH).


AB)
(300 MHz, DMSO d6/D2O): 6.75-6.85(m, 1H, CH aromatic); 7.00-7.05



(m, 1H, CH aromatic); 7.05-7.10(m, 1H, CH aromatic).


AC)
(300 MHz, DMSO d6/D2O): 8.24(s, 1H, CH═N); 5.20(d, J=5.2Hz, 1H,



β-lactam-H); 4.07(d, J=5.2Hz, 1H, β-lactam-H); 3.89 and 3.61(ABq,



J=17.8Hz, 2H, SCH2).


AD)
(300 MHz, DMSO d6/CD3CO2D+CF3COOD): 8.67(s, 1H, CH═N); 5.38-



5.40(2d, 2H, 2β-lactam-H); 4.01(s, 3H, CH3—O); 3.98-4.00(ABq, 2H,



SCH2).


AE)
(300 MHz, DMSO d6): 8.14(s, 1H, CH═N); 5.33(d, J=5.6Hz, 1H, CH);



4.80(d, J=5.6Hz, 1H, CH); 3.88 and 3.58(ABq, J=17.8Hz, 2H, SCH2).


AF)
(300 MHz, DM50 d6): 7.96(s, 1H, CH═N); 5.17(d, J=5.2Hz, 1H, CH);



5.02(d, J=5.2Hz, 1H, CH); 3.96 and 3.47(ABq, J=17.7Hz, 2H, SCH2).


AG)
(300 MHz, DMSO d6): 8.35(s, 1H, CH═N); 5.31(d, J=5.1Hz, 1H, CH);



5.14(d, J=5.1Hz, 1H, CH); 4.28 and 3.84(ABq, J=17.9Hz, SCH2).


AH)
(300 MHz, DMSO d6): 8.41(s, 1H, CH═N); 5.34(d, J=5.1Hz, 1H, CH);



5.18(d, J=5.1Hz, 1H, CH); 4.37 and 3.80(ABq, J=17.9Hz, SCH2).


AI)
(300 MHz, DMSO d6): 8.61(s, 1H, CH═N); 5.36(d, J=5.1Hz, 1H, CH);



5.18(d, J=5.1Hz, 1H, CH); 4.42 and 3.71(ABq, J=18.0Hz, SCH2); 2.74



(s, 3H, SCH3).


AJ)
(300 MHz, DMSO d6): 8.52(s, 1H, CH═N); 5.36(d, J=5.1Hz, 1H, CH);



5.21(d, J=5.1Hz, 1H, CH); 4.46 and 3.79(ABq, J=17.7Hz, 2H, SCH2);



2.95(s, 3H, N—CH3).


AK)
(300 MHz, DMSO d6): 8.51(s, 1H, CH═N); 7.56-6.84(m, 110H, 2Ph);



5.28(d, J=4.8Hz, 1H, CH); 5.00(d, J=5.1Hz, 1H, CH); 4.13 and 3.93



(ABq, J=16.8Hz, 2H, SCH2).

## Claims

1. A trihydrochioride of 1-[hydrazino(methylimino)methyl]piperazine.

2. A compound having the following structure:




or a pharmaceutically acceptable acid addition salt thereof.